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Ataxia telangiectasia mutated (ATM) is a critical component of the cellular response to DNA 
damage, where it acts as a damage sensor, and signals to a large network of proteins which 
execute the important tasks involved in responding to the damage, namely inducing cell cycle 
checkpoints, inducing DNA repair, modulating transcriptional responses, and regulating cell 
death pathways if the damage cannot be repaired faithfully.  We have now discovered that an 
additional novel component of this ATM-dependent damage response involves induction of 
autophagy in response to oxidative stress.  In contrast to DNA damage-induced ATM 
activation however, oxidative stress induced ATM, occurs in the cytoplasm, and does not 
require nuclear-to-cytoplasmic shuttling of ATM. Using several cell culture systems including 
MCF7 breast carcinoma cells, SKOV3 ovarian cancer cells, and various lineages of mouse 
embryonic fibroblasts, we showed that once activated by reactive oxygen species (ROS), ATM 
signals to mTORC1 to induce autophagy via the LKB1-AMPK-TSC2 pathway. Targeting 
dysregulation of mTORC1 in Atm-deficient mice, which succumb to lymphomagenesis within 
3-4 months of age with daily administration of rapamycin, could significantly extend survival 
and cause regression of tumors, suggesting that pharmacologically targeting this pathway has 
therapeutic implications in cancer.  
 We also identified a second contrasting pathway for DNA damage-induced mTORC1 
repression which does not require AMPK activation, but does require ATM and TSC2.  Several 
potential mechanisms including mTOR localization and p53-mediated pathways were ruled out 
vi 
however we identified that TSC2 may be an additional cytoplasmic direct ATM substrate that is 
engaged in response to DNA damage specifically.   
 Lastly, a study was performed to examine whether autophagy induced by ovarian 
cancer therapeutics (focusing on cisplatin, since paclitaxel does not induce autophagy in the 
SKOV3 cell line model we used) plays a role in resistance to therapy since autophagy can play 
both pro-survival mechanisms or be a mechanism of cell death.  Using a genetic approach to 
knock-down Atg5 expression with shRNA in SKOV3 ovarian carcinoma cells, we compared 
the cytotoxicity of cisplatin in vector or Atg5 knock-down cells, and demonstrated that 
autophagy does not play any significant role in the response to cisplatin in this cell line.   
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1 
Introduction 
 
 
1.1 DNA damage and DNA damage response 
Cellular DNA is constantly under attack by a variety of exogenous sources of damage and 
endogenous processes, causing 10,000-100,000 DNA lesions every day per cell  (1). As a 
result, cells have evolved intricate mechanisms to detect and repair such damage to survive 
such insults. Failure to do so faithfully results in mutations, genomic instability, or even cell 
death, and has been implicated in many diseases including cancer (2). This process has been 
termed the DNA damage response (3). 
 Damage to DNA can occur due to spontaneous base chemical modifications (including 
oxidation by reactive oxygen species, methylation or hydrolysis via deamination reactions) or 
replication errors. These endogenous sources of damage are mostly unavoidable since they 
occur as a consequence of normal metabolic processes. The other major source of DNA 
damage is exogenous mutagens such as many chemotherapeutic drugs (e.g. etoposide, 
doxorubicin, cisplatin), ultraviolet and ionizing radiation, and man-made chemicals such as 
polyaromatic hydrocarbons. A variety of different lesions are generated depending on the type 
of damage, including base modifications, DNA adducts, inter- and intra-strand crosslinks, 
single- or double-strand breaks, which are the most lethal forms of damage. These lesions and 
downstream consequences are described in more depth in figure 1. 
 Responses to DNA damage involves a cascade of proteins, beginning with a series of 
damage sensors, which transmit signals via transducer proteins (mostly kinases which amplify 
this signal) to effector proteins which execute the various processes in the cell.  These well-
described processes include cell cycle checkpoints, recruitment of DNA repair factors to the 
sites of damage, transcription around the damage and if the damage is too severe to be 
repaired, induction of apoptosis.  In this thesis, I describe a previously unappreciated aspect of 
cellular responses to damage, namely mTORC1 repression and induction of autophagy in 
response to ROS.
2 
Figure 1: 
 
 
 
 
Figure 1: Types of DNA damage, sources and cellular responses to damage. Illustration 
showing both endogenous and exogenous sources of DNA damage, types of lesions 
generated, and downstream cellular consequences. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Cancer (4) Copyright 2003 
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 If the damage cannot be repaired in an error-free manner, one of the potential 
consequences is the development of cancer. The evidence for this relationship came from a 
number of studies from cell culture, animal models and human tumors, showing that the DNA 
damage response (ie markers of double strand breaks and downstream ATM-dependent 
pathways) could be detected in precursor lesions, leading to cell senescence or apoptosis, 
thereby acting as an anti-cancer barrier (5).  In addition, oncogenes such as Myc have also 
been shown to directly induce DNA damage (6, 7) and activate the DNA damage response to 
induce apoptosis, whereas cells that have lost tumor suppressor gene function, such as p53-
deficient cells, possess a constitutively active DNA damage response, as measured by Chk2 
phosphorylation and 53BP1 localization at DSB (8).  Taken together these results provide 
insights into the mechanisms of DNA damage response pathways, which is likely to lead to 
better ways of eliminating damaged cells that may eventually lead to tumors. 
 
1.2 Reactive oxygen species (ROS) 
ROS are highly reactive oxygen-containing molecules that can damage cells via reversible or 
irreversible reactions with proteins, lipids and DNA.  These ROS molecules can either contain 
one or more unpaired electrons (known as “free radicals”) or be a non-radical species, which 
although do not contain any unpaired electrons, are still chemically reactive and may be 
converted to radical species.  The most commonly encountered forms of ROS in biological 
systems are listed in table 1. When levels of ROS are increased beyond a threshold where the 
cell can manage, the cell encounters a state known as oxidative stress.   
 
4 
Table 1: 
 
Free radical species Non-radical species 
Superoxide O2- Hydrogen peroxide H2O2 
Nitric oxide NO Peroxynitrite ONOO- 
Hydroxyl radicals OH- Hydroxide OH 
  Ozone O3 
 
 
Table 1: Summary of major forms of ROS in biological systems and their chemical 
formulas.
5 
  In spite of their ability to cause cellular damage, ROS play important physiological 
functions in regulating signaling pathways including cell growth/cell death pathways and 
differentiation (9, 10).  At a biochemical level, ROS such as hydrogen peroxide can directly 
oxidize protein phosphatases and kinases, growth factor receptors and transcription factors. At 
the organismal level, they can also initiate inflammatory responses via upregulation of 
cytokines, and can influence the immune response.  Mitochondria are the main physiological 
sources of ROS, which is generated when electrons leak from the respiratory chain and react 
with molecular oxygen (O2) to form superoxide which can then be readily converted to other 
forms of ROS.  In addition to the mitochondria, the peroxisome is a major source of ROS 
generated as a byproduct of β-oxidation of fatty acids, and detoxification reactions by 
cytochrome P450 enzymes. 
There is now an extensive body of literature describing the significant roles that 
oxidative stress plays in the pathogenesis of a variety of metabolic, cardiovascular, 
neurodegenerative diseases, as well as in the induction and promotion stages of cancer (11-
14). The metabolic syndrome, a collection of risk factors for cardiovascular disease, including 
increased body mass index, hypertension, elevated blood glucose and triglycerides has been 
attributed to a systemic increase in oxidative stress, which may also partially explain the link 
between metabolic syndrome and cancer (15, 16). In cancer, there is a delicate balance of 
ROS, since although there is increased generation of ROS due to higher metabolic rates, 
dysfunctional mitochondria as a result of deregulated oncogene activity, cancer cells also 
express higher levels of antioxidant enzymes (6, 17-20).  However, the net effect is still a 
higher than baseline level of ROS which plays critical roles in cell function (21). 
In cancer, ROS can directly induce mutations in both nuclear and mitochondrial DNA, 
and function as signaling molecules to regulate cell growth and differentiation, glucose 
metabolism, and inflammation (14). Some important examples of pathways regulated by ROS 
include the MAPK/ERK pathway (for example via Ras oxidation leading to activation) and the 
PI3K/AKT pathway (via PTEN inactivation) (22-26). The other important pathway that is 
6 
activated by oxidative stress is the IKK-NF-κB pathway. To deal with the constant barrage of 
stress, cells must possess intricate defense mechanisms for continued survival.  These fall 
into 2 broad classes, one involving upregulation of antioxidant enzymes such as superoxide 
dismutase and catalase (27) and the other being induction of DNA repair pathways for 
example, via Gadd45 (28). 
 
1.3 ATM 
The locus involved in the the disease ataxia telangiectasia was mapped to chromosome 
11q22-23 in 1988 and it took 7 more years for the gene to be cloned by the Shiloh laboratory 
(29, 30). AT is a systemic disease affecting many organ systems.  The two most prominent 
pathological features of this disease are a significant propensity to spontaneously develop 
hematopoietic malignancies (leukemias and lymphomas), and a progressive 
neurodegeneration involving loss of cerebellar neuronal function, that leads to the ataxia 
phenotype.  As a result, most patients do not live beyond their second or third decade of life.  
However beyond these major symptoms, patients have other abnormalities including 
metabolic defects, immunodeficiency and are hypersensitive to ionizing radiation.  It was this 
last phenotype that first lead to the discovery of ATM’s cellular function, although this wide 
spectrum of defects suggestions that ATM may play pleiotropic functions. 
 The best characterized function played by ATM in the cell is as a DNA damage sensor. 
As a “first responder” to DNA double-strand breaks, the ATM protein, which has kinase 
enzymatic activity, serves as an initiator of many pathways including DNA repair, induction of 
cell cycle checkpoints, and if necessary induction of cell death (apoptosis) if the damage is too 
severe to be repaired (31, 32).  These pathways are triggered via ATM phosphorylation of 
transducer proteins which signal to effector proteins, as shown in the schematic in figure 2. 
 The mechanism of ATM activation by DNA damage has now been fairly well described.  
Upon double-strand break occurrence, ATM dimers are rapidly recruited to the broken DNA  
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Figure 2: 
 
 
 
Figure 2: Hierarchy in signaling pathways in response to DNA damage. Illustration shows 
that ATM acts as a proximal sensor of DNA damage (double strand breaks) initiating signaling 
via a cascade of proteins that are transducers to effector proteins. [From (33) under creative 
commons license (URL: 
http://atlasgeneticsoncology.org/Deep/DoubleStrandBreaksID20008.html)] 
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Figure 3: 
 
 
 
 
Figure 3: Structure of ATM protein. Schematic showing the domains found in ATM and other 
family members. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Cancer (4) Copyright 2003 
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ends.  In a dimer structure, ATM is inactive because the kinase domain of one molecule of 
ATM is blocked by the FAT domain of the other molecule (4).  Figure 3 illustrates the different 
domains in the ATM family of proteins. In order to convert these dimers to an active form via 
transphosphorylation of a serine residue (S1981 in human/S1987 in mouse) which releases 
active monomers which can now signal to downstream substrates containing consensus 
phosphorylation sites of SQ/TQ. 
 The requirement for phosphorylation at S1981/S1987 has recently been called into 
question from studies utilizing a mutant protein lacking this phosphorylation site.  If 
phosphorylation of S1981/7 was required for ATM activation, then this mutant would be 
expected to be unable to reconstitute ATM function in ATM-deficient cells and even function as 
a dominant negative.  Surprisingly, MEFs generated from a knock-in mouse where Ser 1987 is 
mutated to alanine had a perfectly functional ATM-dependent DNA damage response (ie 
phosphorylation of Smc1 and chk2, and recruitment to double strand breaks), and the mouse 
developed normally (34). These results suggest that S1987 autophosphorylation is not a 
mechanism of ATM activation, but rather is a consequence of ATM activation. 
 Other posttranslational modifications involved in ATM activation have also been 
identified, including four more autophosphorylation sites and acetylation.  In response to DNA 
damage therefore a total of five autophosphorylation sites are increased - S367, T1885, 
S1893, S1981 and  S2996 are increased in an ATM and Mre11-dependent manner (35, 36). 
These sites are all individually important in full ATM function in classical DNA damage 
responses such as cell cycle checkpoint induction and DNA repair, since single alanine 
mutants fail to correct the defect in ATM-deficient cells.  Several years ago, DNA damage-
inducible acetylation of a C-terminus lysine was identified (37, 38). This rapid modification by 
the Tip60 acetyl transferase results in activation of ATM’s kinase activity, promotes the 
conversion of the inactive dimers to active monomers, therefore allowing phosphorylation of 
ATM substrates such as p53 and Chk2.  Another acetyltransferase called hMOF is also 
upstream of ATM and can directly interact with ATM (39). However a direct acetylation site has 
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not been identified.  Rather hMOF’s HAT activity towards H4K16 plays a role in regulating 
ATM activation, by a poorly characterized general mechanism involving altered chromatin 
structure. 
 In unstressed conditions, ATM autophosphorylation is inhibited by the presence of 
phosphatases, including protein phosphatase 2A (PP2A), which interacts physically with ATM 
via its scaffolding subunit (40).  Upon damage by ionizing radiation, PP2A dissociates from 
ATM, allowing the previously described activation mechanisms to proceed.  In contrast to this 
mechanism, another serine-threonine protein phosphatase, PP5 interacts with ATM in a DNA 
damage-inducible manner, and is important for ATM activation by removing other inhibitory 
phosphorylation groups (41). 
 ATM is known to be phosphorylated in response to a number of types of stresses 
beyond DNA damage, including replication stress (secondary to ATR activation). Large scale 
chromatin structure alteration such as that which occurs after treatment with HDAC inhibitors, 
or chloroquine also has been shown to regulate ATM activation (42).  Also of importance to 
this thesis as a whole is the observation the ATM is activated by oxidative stress.  
 Interestingly, the mechanism of ATM activation by oxidative stress has now been 
shown to occur by a separate mechanism from the DSB-mediated pathway, although ROS 
can cause DNA base damage that can be converted to DSBs in the process of being repaired.  
The first paper identifying a direct link between oxidative stress and ATM activation showed 
that free sulfhydryl (SH) groups on cysteines could be modified in response to 2 agents that 
generate ROS: N-methyl-N’-nitro-nitrosoguanidine (MNNG) and 15-deoxy-Δ12,14 prostaglandin 
J2, which is a more physiological compound produced during inflammation during prostaglandin 
D2 metabolism (43). ATM could be activated both in vitro and in vivo in an NBS1 and MSH6-
deficient background, demonstrating that DNA damage is not the only mechanism of ATM 
activation. ROS is also produced as a byproduct of UVA radiation which can activate ATM to 
induce apoptosis (44).  In polyglutamine diseases arising from long CAG repeat tracts, such as 
Huntington’s disease, ATM is also activated as a result of the ROS generated by these protein 
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aggregates, which is thought to contribute to the neurodegenerative symptoms of the disease 
(45). More recently Tanya Paull’s group showed that ROS can directly oxidize ATM at Cys 
2991, which promotes formation of a disulfide-crosslinked ATM dimer that is active (in contrast 
to the DNA damage activated ATM which is a monomer) (46).  In chapter 3 of this thesis I 
show that ROS can robustly activate both nuclear ATM (likely as a result of DNA damage) as 
well as cytoplasmic ATM, and that this specific pool of ATM can signal to LKB1, AMPK, TSC2 
and mTORC1 to induce autophagy. 
 
1.3.1 ATM subcellular localization 
ATM’s functions in sensing DNA damage and signaling to DNA repair and cell cycle 
checkpoints would strongly suggest that this protein is localized to the nucleus.  Indeed, this is 
the case; however a substantial portion can be localized to organelles outside of the nucleus. 
Subcellular fractions from lymphoblastoid and fibroblasts were probed with antibodies to ATM, 
and ATM was detected in the nucleus.  In addition about 20% of the total cellular pool of ATM 
was found in the microsomal fraction in vesicles of varying size (from 60-230nm) (47). This 
was confirmed by electron microscopy using immunogold-conjugated secondary antibodies. 
The punctate staining seen in these studies led to the discovery that a portion of these 
vesicles were peroxisomes, and that ATM could be delivered to peroxisomes via binding to the 
type 1 import receptor, peroxin 5.  In chapter 4, I will elaborate further on the localization and 
function of ATM that is localized at the peroxisome. 
 Apart from the peroxisome, the other vesicular organelle that ATM has been found to 
reside in is the endosome (48). ATM was found to directly interact with β-adaptin using a yeast 
2-hybrid screen. β-adaptin is a component of the clathrin-mediated receptor endocytosis 
pathway.  This interaction was confirmed in vivo and a neuronal-specific β-adaptin homolog β-
NAP (which was identified as an autoimmune antigen in a patient with cerebellar 
degeneration) was also determined to be an ATM binding partner suggesting that ATM may 
have physiological functions in the endocytic pathway.  
12 
 ATM has also been reported to be recruited to the plasma membrane by the casein 
kinase-2 interacting protein-1 (CKIP-1), and is phosphorylated at S1981 when membrane-
localized (49). CKIP-1 is plays a number of seemingly distinct roles in processes ranging from 
muscle differentiation, to regulation of the actin cytoskeleton and recruiting casein kinase 2 to 
the plasma membrane.  While the in vivo relevance of ATM localized to the plasma membrane 
is not completely clear, it appears that ATM plays a role in CKIP-1 mediated phosphorylation 
and stabilization of p53.  Interestingly, ATM deficient cells have been reported to have 
cytoskeletal defects and structural abnormalities in the plasma membrane (50). The interaction 
with CKIP-1, and subsequent regulation of actin therefore may partially explain these structural 
defects in AT-cells.  
 Genomic instability is one of the hallmarks of ATM-deficient cells, attributed both to the 
DNA repair and cell cycle checkpoint functions that are regulated by ATM, as well as an extra-
nuclear role at the centrosome.  There are now several pieces of evidence regarding ATM 
playing an important role in the spindle.  At the gross level, ATM-deficient cells have both 
numerical and structural chromosomal instability, and in an Atm-deficient background p21 
could suppress aneuploidy (51).  The ATM-p53-p21 damage response pathway has been 
shown to be activated early on during tumorigenesis (5), and centrosome amplification is also 
an early event during tumorigenesis, leading to the hypothesis that ATM could play a role in 
maintaining appropriate centrosome number as an additional mechanism of controlling 
genomic stability. Several years ago, Shen and co-authors reported that ATM could be 
detected in purified centrosomes (51), and this study also provided direct evidence that ATM 
deficiency induced centrosome amplification.  The mechanism for ATM regulation of 
centrosome number appears to require p53 and p21, since Atm, p21 double knockout MEFs 
or Atm, p53 double knockout MEFs did not display a more severe centrosome amplification 
phenotype, suggesting these proteins are epistatic.  ATM is activated with relatively slow 
kinetics (8-24 hours) by mitotic stresses like nocodazole or taxol, further implicating a role in 
the mitotic stress response. One additional potential mechanism for ATM activity at the 
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centrosome is via regulating polo-like-kinase 1 in response to mitotic stress, which is 
prematurely elevated in ATM-deficient cells (52). 
 
1.3.2 ATM cellular trafficking 
The studies described above regarding different subcellular localizations of ATM raises an 
interesting question regarding whether ATM shuttles between these compartments or whether 
there are distinct pools of ATM that reside in these locations, perhaps with different functions. 
Recent studies have shown that indeed ATM can shuttle out of the nucleus in a mechanism 
first described by Wu et al (53).  As a result of DNA double-strand breaks and ATM activation, 
ATM phosphorylates NEMO, which is a regulatory subunit of the I-κB kinase, at Ser 85, which 
serves as a signal for mono-ubiquitination of NEMO.  This modification allows NEMO and ATM 
to translocate out of the nucleus where NEMO serves as an adaptor protein to bring together 
the IKK complex and ELKS (another regulatory subunit), activating this signaling cascade, 
which allows activated NF-κB to re-enter the nucleus to transcriptionally regulate anti-apoptotic 
genes.  However, my work that will be described in chapter 3 suggests that in addition to 
shuttling, there are distinct cytoplasmic pools of ATM, suggesting that differential localization 
of ATM can dictate what functions it plays. 
 
1.4 TSC2 regulation of mTOR 
Tuberous sclerosis complex (TSC) is a highly penetrant autosomal dominant disease caused 
by mutations in either the TSC2 (tuberin) or TSC1 (hamartin) tumor suppressor genes.  
Patients with TSC develop benign hamartomas in a wide range of tissues early in life.  The 
brain is the most common organ affected by 3 main types of lesions: giant cell astrocytomas, 
cortical tumors and subependymal nodules (54).  These tumors cause the bulk of the morbidity 
associated with TSC, due to causing seizures that may affect learning, memory and behavior, 
depending upon their size and location.  In addition to the brain, tumors often arise in the 
kidneys (angiomyolipomas, or rarely renal cell carcinomas), lungs (similar to 
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lymphangioleiomyomas, but thought to be metastases from angiomyolipomas), heart (cardiac 
rhabdomyosarcomas) as well as facial angiofibromas (54). Currently there is no cure for 
tuberous sclerosis complex, however recent studies with mTOR inhibitors have had promising 
results in reducing tumor size. 
These GTP-ase activating proteins (GAP) function as a heterodimer in the cell, to 
negatively regulate cell growth via inhibiting the Rheb GTPase.  Rheb functions as an activator 
of mTORC1, so the net result of TSC2 activation is mTORC1 repression (55).  In the following 
section I will describe mTOR function more thoroughly. 
 
1.4.1 mTOR 
The mammalian target of rapamycin (mTOR) is an important serine-threonine kinase that 
belongs to the phosphoinositide-3-kinase (PI3K)-related family of kinases (PIKKs) that 
includes ATM, ATR, DNA-PK and hSMG1. TOR is conserved across eukaryotes from yeast to 
mammals, and is required for development in mouse, worms (C. elegans) and drosophila due 
to an early block in cell growth when this gene is deleted (56-59). 
mTOR exists in two distinct large protein complexes know as mTORC1 and mTORC2, 
which have a number of differences (and similarities) (60).  One major difference is the 
composition of these complexes: mTORC1 complex contains mTOR, raptor, mLST8, PRAS40 
and Deptor, whereas mTORC2 contains mTOR, rictor, mLST8, Deptor, mSIN1, and Proctor-1. 
These complexes and example substrates are depicted in figure 4.   Importantly, rapamycin 
can only bind and inhibit the mTORC1 complex through binding to FKBP12, which is why 
mTORC1 became known as the “rapamycin-sensitive” complex, whereas at least upon acute 
treatment with rapamycin, mTORC2 (thought to be “rapamycin-insensitive”) substrates are 
unaffected.  However it is known that prolonged exposure to rapamycin can affect mTORC2 
activity via destabilizing this complex in certain cell lines, therefore inhibiting AKT, one of the 
best characterized substrates of mTORC2 (61). 
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Figure 4: 
 
 
 
 
 
Figure 4: mTOR complex schematic mTOR is a component of two distinct protein complexes 
known as mTORC1 and mTORC2 that have different downstream substrates.  S6K and 4E-
BP1 are the most frequently used mTORC1-specific substrates, while AKT is the most 
frequently used mTORC2-specific substrate.  
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mTOR regulates many substrates important in translation, cell size and autophagy. 
One of the earliest identified substrates of mTORC1 was S6K, which was found to be 
upstream of ribosomal protein S6 (known as S6), involved in protein synthesis.  Another  
important mTOR substrate is 4E-BP1, which binds to eukaryotic initiation factor 4E (eIF-4E) 
inhibiting its function.  When 4E-BP1 is phosphorylated (and inactivated) by mTORC1, eIF-4E 
is released from this complex, forming a complex with eiF4G, eiF4A and eiF3 ribosomes, 
which enhances translation of 5’ capped mRNAs (63, 64).  The substrates that are important in 
regulating autophagy are less well characterized, and will be described further in the section 
on autophagy. 
mTOR plays a very important role in cellular and organismal homeostasis due to its 
central role in regulating metabolic processes both anabolic and catabolic in response to 
diverse stimuli such as nutrients, energy, growth factor signaling, oxygen and stresses such as 
DNA damage (65). In addition I have shown that oxidative stress can serve as a regulator of 
mTOR activity via signaling from ATM, as described in chapter 3. 
 
1.4.2 Regulation of TSC2 
TSC2 serves as a nexus in the cell, since it is regulated by multiple upstream mitogenic and 
energy sensing pathways, and its cellular localization also plays a role in its activity.  Under 
conditions of nutrient deprivation, TSC2 activity is increased via phosphorylation by AMPK at 
Thr 1227 (Thr 1271 in human) and Ser 1345 (Ser 1387 in human), however other sites 
including Ser 1337 and Ser 1341 are impacted as a result of mutation of Ser 1345.  AMPK 
activation of TSC2 plays a major role in turning off mTORC1 (ie phosphorylation of S6K) in 
response to glucose deprivation (ATP depletion), which acts as a survival mechanism to low-
energy (66). AMPK phosphorylation of TSC2 at Ser 1345 also functions as a priming event for 
further activation of TSC2 activity via the Wnt-GSK pathway which is independent of β-catenin 
activity (67). Wnt signaling therefore acts as a TSC2 activation mechanism via inhibiting 
GSK3-mediated phosphorylation which is normally an inhibitory event. 
17 
When cellular levels of AMP rise due to energy deprivation (therefore increasing the 
AMP:ATP ratio), AMP binds to the γ-subunit of AMPK (which is a heterotrimer consisting of a 
catalytic subunit, AMPKα and 2 regulatory subunits called AMPKβ and AMPKγ). This binding 
has been proposed to induce a conformational change in the AMPK complex which improves 
the ability of AMPKα to serve as a substrate for upstream kinases such as LKB1. 
 In contrast to AMPK-mediated activation of TSC2, when cells are stimulated with 
mitogens or growth factors, the PI3K-AKT pathway is activated.  As a result, AKT 
phosphorylates and inactivates TSC2 (68-70) which promotes binding to 14-3-3 in the 
cytoplasm (71).  Five independent AKT phosphorylation sites have been identified, which are 
shown in figure 5. 
.  Our lab has previously shown that TSC2 functions in a cellular endomembrane 
compartment when active, and that as a result of inactivation by AKT, leaves this compartment 
and binds to 14-3-3 (72). This model for localization-dependent activity of TSC2 is depicted in 
figure 6.  
In addition to activating the PI3K-AKT pathway, mitogens activate the MAPK/ERK 
pathway which has also been shown to inactivate TSC2 via phosphorylation.  Two direct ERK 
phosphorylation sites, Ser 540 and Ser 664 have been shown to be involved in inhibition of 
TSC2 function via dissociating the TSC2:TSC1 complex (73).  In addition, in response to 
phorbol esters or activated Ras, RSK can phosphorylate TSC2 in an AKT-independent 
manner on Ser 1798 and Ser 664 which are inhibitory signals as well (74).  Figure 5 
summarizes all the known phosphorylation sites on TSC2 that have been described in this 
section.  
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Figure 5: 
 
 
 
 
Figure 5: TSC2 phosphorylation sites based on human nomenclature A schematic 
showing the major phosphorylation sites in human TSC2 protein and their upstream kinases 
19 
Figure 6: 
 
 
 
Figure 6: Model depicting TSC2 localization and function Active TSC2:TSC1 heterodimers 
are found in an endomembrane compartment where they can associate with Rheb maintaining 
it in an inactive GDP-bound form. Upon growth factor stimulation, AKT phosphorylates TSC2 
and causes it to leave the membrane and bind to 14-3-3, and as a result Rheb become bound 
to GTP which allows activation of mTOR (mTORC1 complex). [Reprinted from (72) under 
Creative Commons License] 
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1.5 Autophagy  
Autophagy is a catabolic process utilized by cells to recycle cellular constituents, via lysosomal 
degradation (75).  There are 3 fundamental forms of autophagy: macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA) which more similar to 
microautophagy (76, 77). Macroautophagy involves de novo formation of an isolation 
membrane which surrounds the cargo to be degraded, in contrast to microautophagy which 
engulfs material directly into the lysosome.  The source of this autophagosome membrane is 
still a controversial area of research, however there is strong evidence that both the plasma 
membrane and the mitochondria can provide these lipids in mammals (78-80) and in yeast the 
golgi has been identified as an additional potential membrane source (81, 82).  Chaperone-
mediated autophagy involves translocation of unfolded proteins across the lysosome 
membrane with the assistance of the chaperone protein Hsc70 which is both in the cytoplasm 
and in the lumen of the lysosome. 
A variety of cellular components are targeted for degradation by autophagy including 
individual proteins, protein aggregates, ubiquitinated substrates and entire organelles can be 
engulfed.  Many organelles are degraded by specific forms of autophagy such as mitophagy 
(for mitochondria), pexophagy (for peroxisomes), ERphagy (for endoplasmic reticulum) and 
ribophagy (for ribosomes).  Once this membrane completely surrounds the cytoplasmic 
material, the vesicle becomes known as the autophagosome, which fuses to the lysosome 
which contains the proteases and other enzymes which degrade the contents.  Figure 7 shows 
a schematic of the autophagy process.  As a result, basic molecular building blocks (such as 
free amino acids and fatty acids) are released back into cells, which avoids the expenditure of 
energy to unnecessarily make these components.  However, autophagy can also be a major 
component of type II non-apoptotic programmed cell death if taken too far. 
 The physiological role for autophagy appears to be primarily a stress response, as 
many types of stresses (including nutrient deprivation, oxidative stress and DNA damage)  
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Figure 7: 
 
 
 
 
 
Figure 7: Schematic of the autophagy process from engulfment of cargo to degradation. 
Autophagy begins by nucleation of an membrane which surrounds the cytoplasmic cargo to be 
degraded, forming an autophagosome, which then docks and fuses with a lysozome carrying 
enzymes such as hydrolases which catalyze the breakdown process in the autolysosomes. 
[Reprinted from (83), under Creative Commons License] 
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induce autophagy, however even unstressed cells have a low basal rate of autophagy for 
turning over long-lived proteins (84). In addition, damaged organelles are often removed by  
autophagy, suggesting that autophagy also plays a quality control mechanism within cells to 
maintain optimal function.  Not all of these pathways are fully characterized, but are being  
actively pursued by many laboratories including our own. It is known that autophagy is 
executed via a ubiquitin-like conjugation system involving a large number of core autophagy 
related genes, which are known as Atg genes (eg Atg5, Atg7 and Atg12). More than 30 Atg 
genes have been identified primarily from studies in yeast, but many have mammalian 
homologs (85). 
 
1.5.1 Autophagy, physiology and disease 
Inappropriate regulation of autophagy resulting from gains or losses of autophagy-regulating 
genes (or lysosomal genes) or dysregulation of signaling pathways that regulate autophagy 
have been linked to the pathophysiology of many diseases, including cancer, 
neurodegenerative disorders, and cardiovascular diseases (86, 87).  A brief description of 
some of the roles of autophagy in physiology and disease will be discussed in the following 
section, but by no means will this be a comprehensive discussion of this broad topic which 
could fill many theses. 
 Autophagy is now thought to be a tumor suppressing mechanism early on in the 
development of tumors, but later on can be subverted by tumors to maintain proliferation 
capacity in spite of metabolic stress, hypoxia or other types of stresses including many types 
of therapy (88).  In normal cells, autophagy plays an important housekeeping/quality control 
role in removing defective proteins and organelles, as well as maintaining genomic stability by 
limiting DNA damage and oxidative stress.  One important protein involved in autophagy 
induction called beclin 1, which is a Bcl-2 interacting protein, has been shown to be a bona 
fide tumor suppressor gene from observations that this gene is monoallelically deleted in 40-
75% of human breast, ovarian and prostate cancers.  When beclin 1 is re-introduced into 
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cancer cells with loss of heterozygosity for beclin 1 (such as MCF7 cells), there is a significant 
decrease in proliferation, clonogenicity and in vivo tumorigenic potential (89). Studies in beclin 
1 heterozygous mice have also supported the notion that beclin 1 is a tumor suppressor, since 
these mice develop more spontaneous tumors from a variety of tissues (including breast and 
lung carcinomas, hepatocellular carcinomas and lymphomas) (90). 
 Once tumors have developed, it is now generally believed that the role of autophagy 
switches to a pro-survival function since the cell can recycle constituents that are no longer 
needed, which serves as a backup energy source to maintain viability.  Metabolic stress 
robustly activates autophagy which prolongs survival in apoptosis-deficient cells (a common 
feature in cancer cells).   Recently Eileen White’s and Alec Kimmelman’s laboratory have 
discovered there are some tumor types that are addicted to autophagy to maintain oxidative 
metabolism, including pancreatic cancers and other Ras-driven tumors, which provides 
rationale for targeting these tumors with autophagy inhibitors such as chloroquine (91, 92).   
There is significant crosstalk between autophagy and apoptosis, such as that seen in 
the DNA damage response, where induction of autophagy can delay apoptosis, and result in 
delayed caspase-independent cell death in noninvasive tumors. Unfortunately once the tumors 
have progressed and developed resistance to the genotoxic damage stimuli, this autophagic 
survival pathway is no longer relevant (93). 
 Autophagy can play a defense role against infection by a large variety of pathogens, in 
addition to more classical endocytic-phagocytic mechanisms of removing bacteria via delivery 
to the lysosome (94). Viruses are another class of pathogens that can be eliminated via 
autophagy.  In contrast to bacterial-induced autophagy which is triggered by bacterial wall 
proteins, virus-induced autophagy is thought to be triggered as a consequence of the host cell 
secreting cytokines such as interferons. Some of these downstream pathways overlap with ER 
stress pathways that utilize the eIF2α family of kinases that positively regulate autophagy, for 
example the dsRNA-dependent protein kinase PKR, PERK and GCN2. For a more detailed 
description of these pathways see (95, 96). 
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 In the brain, autophagy is thought to be particularly important in neuroprotection, in its 
quality control role (97, 98). Since most mature neurons don’t divide, individual cells must rely 
on basal autophagy to remove damaged organelles, unlike other somatic cycling cells which 
can gradually dilute out damaged organelles during cell division, even if there are minor 
decreases in autophagic flux over time.  A large number of adult-onset neurodegenerative 
disorders have been linked to defective autophagy involving both decreased autophagosome 
formation as well as later stages of fusion and lysosomal degradation. Some particularly 
notable examples of diseases with strong evidence for defective autophagy are Alzheimers 
disease, ALS and Parkinson’s disease. The ubiquitin ligase, Parkin and upstream kinase 
PINK1 are proteins that are frequently mutated in Parkinson’s disease, and these proteins 
both are important in mitophagy of mitochondria with low membrane potential (99).  In 
Parkinson’s disease, the accumulation of damaged mitochondria is thought to be important in 
the pathophysiology of the disease.  However autophagy not only is important for organelle 
homeostasis but also in the removal of aggregation-prone proteins, which are often caused by 
the disease-linked genetic mutations and are major sources of toxicity, such as tau in 
Alzheimers disease. Research into mechanisms of pharmacologically upregulating autophagy 
in a tissue-specific manner in these disease settings is now a major area of interest for 
pharmaceutical companies. 
 
1.5.2 Regulation of autophagy 
Over the past 10 years, a large number of signaling pathways have been identified as 
autophagy regulatory mechanisms, most of which promote autophagy induction.  mTORC1 
was the first pathway identified however that negatively regulates autophagy.  While the 
precise mechanism remained elusive for many years, recently ULK1 has emerged as an 
mTORC1 substrate involved in regulating an early step in autophagosome formation (100-
102).  ULK1 is a part of a large protein complex in cells that also contains FIP200 and ATG13, 
which are both required for the localization of this complex to the isolation membrane and for 
25 
regulating the kinase activity of ULK1. A dual model has now emerged involving multiple 
phosphorylation events by AMPK or mTORC1 depending upon energy status.  When cells are 
starved, AMPK is activated, and promotes autophagy via phosphorylating ULK1 at Ser 317 
and Ser 777.  However when nutrients are not limiting, mTORC1 activity is elevated, and as a 
result a different ULK1 phosphorylation site (Ser 757) is increased, which disrupts the 
interaction between AMPK and the ULK1 complex (103).   
 Another pathway for regulation of autophagy that has particular relevance to our 
studies is p53, one of the most frequently mutated genes in cancer (104, 105).  p53 is a 
transcription factor that is stabilized in response to many types of stresses, and as a result 
transcriptionally regulates many genes important in damage responses, including DNA repair, 
cell cycle checkpoints and senescence.  However in addition to these roles it also regulates 
autophagy by two separate mechanisms that are dependent upon its cellular localization.  
Nuclear p53 has been shown to positively regulate autophagy by transcriptionally upregulating 
genes such as sestrin 2, DRAM and ISG20L1 (106-108).  However cytoplasmic p53 can also 
inhibit autophagy via inhibiting AMPK (109), and it is this function of p53 which is usually 
dominant in cells. 
 All three major MAPK kinase pathways have been shown to regulate autophagy.  
ERK1/2 have been shown to promote autophagy in human colorectal carcinoma cells via 
phosphorylating Gα-interacting protein (110). This process was later shown to be antagonized 
by amino acid induced inhibition of Raf1, which is upstream of ERK activation (111). In 
addition to general macroautophagy induction, ERK2 has been shown to positively regulate 
mitophagy, a specific form of autophagy that degrades mitochondria (112). In general, it has 
been shown that ERK-regulated autophagy leads to type II-programmed cell death in 
response to a variety of toxicants or secondary to neuronal disease (113-117).  The JNK arm 
of the MAPK pathway also promotes autophagy, however the functional outcome is much 
more variable.  ER-stress induced JNK activation leads to enhanced survival (118), where as 
JNK that is activated by etoposide, staurosporine, or with ceramide (which is a cellular second 
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messenger in stress and radiation responses), autophagic cell death occurs (119, 120). A non-
canonical form of autophagy that is dependent on ERK and JNK activation, but is beclin 1 
independent has been reported to be induced in response to ROS in cancer cells, and this 
autophagic response results in cell death by both autophagy and apoptosis (121).  In this 
report, Atg 7 was identified as a downstream target of JNK activity.  In contrast to ERK and 
JNK, the p38α MAPK has been shown to inhibit both basal and starvation-induced autophagy 
via interfering with Atg9 translocation from the transgolgi network to the autophagosome 
membrane by competing for binding to a newly identified p38-interacting protein called p38IP 
(122).  p38α is known to be activated by osmotic stress and also after ionizing radiation. The 
functional consequence of autophagy inhibition by p38 is not completely clear, although one 
study showed that treatment of colorectal cancer cells with a p38 inhibitor resulted in 
autophagic cell death, suggesting that activation of p38 is a survival mechanism (123, 124). 
 Transforming growth factor β (TGFβ), a multifunctional cytokine that regulates growth 
and differentiation of many cell types also promotes autophagy in hepatocellular carcinoma 
and mammary carcinoma cells (125).  This mechanism of autophagy regulation requires both 
type I and type II receptors, and involves both activation of Smads, as well as signaling via 
JNK, which as previously described induces autophagy.  Many of the classic molecules that 
are important in autophagy are upregulated by TGFβ exposure, including beclin 1, ATG5, 
ATG7 and DAPK. 
 A final potentially relevant pathway of regulating autophagy in response to damage is 
the RB-E2F pathway. The first study implicating this pathway found that E2F1 could directly 
transcriptionally regulate a number of autophagy regulating genes including LC3, ATG1, ATG5 
and DRAM (126). Later studies showed however that E2F1 can also inhibit autophagic flux via 
blocking fusion of the autophagosome with the lysosome (127, 128). DNA damage can 
activate E2F1 via ATM/ATR phosphorylation of Ser 31 which promotes stabilization of the 
protein (129). 
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Materials and Methods 
 
 
2.1 Antibodies, equipment and reagents 
A complete list of antibodies used may be found in table 2, and were from the following 
companies: Cell Signaling Technologies (Danvers, MA), Sigma-Aldrich (St. Louis, MO), Santa 
Cruz Biotechnology (Santa Cruz, CA), Epitomics (Burlingame, CA), R&D Systems 
(Minneapolis, MN), BD Biosciences (San Diego, CA), Zymed/Invitrogen (Carlsbad, CA) Abcam 
(Cambridge, MA) and GeneTex (Irvine, CA). 
 Most of the reagents we utilized were purchased from Sigma-Aldrich (St. Louis, MO) 
including hydrogen peroxide (H2O2, which was purchased fresh approximately monthly), N-
acetyl cysteine (which was dissolved in water immediately prior to treatment), DMSO, 
etoposide (which was dissolved in DMSO), doxorubicin (which was dissolved in water), 
neocarzinostatin, bovine catalase (which was dissolved in 50mM potassium phosphate buffer), 
and chloroquine (which was dissolved in water immediately prior to treatment). Compound C 
was from EMD/Calbiochem (San Diego, CA). Rapamycin, leptomycin B and cisplatin were 
purchased from LC Laboratories (Woburn, MA). 
 Cells were irradiated in closed plates with a Rad Source 2000 (Suwanee, GA) irradiator 
and returned to a 37°C incubator until harvesting.  All cell media was purchased from 
Invitrogen (Carlsbad, CA) as pre-made solutions except for F12K which was purchased from 
American Type Culture Collection (ATCC).  Fetal bovine serum was purchased from 
Hyclone/Fisher Scientific (Logan, UT) or more recently, Sigma-Aldrich (St. Louis, MO).  
Geneticin (G418) and puromycin were purchased from Sigma-Aldrich (St. Louis, MO). 
 
2.2 Cell culture 
All cells were grown in antibiotic-free conditions, except as described below, in a humidified 
37°C incubator with 5 or 10% CO2. MCF7 breast carcinoma cells (from ATCC) were  
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Table 2 
Protein Source Catalog # 
4E-BP1 Cell Signaling Technologies 9452 
Phospho-4E-BP1 (T37/46) Cell Signaling Technologies 9459 
ACC Cell Signaling Technologies 3662 
Phospho-ACC (S79) Cell Signaling Technologies 3661 
AMPK Cell Signaling Technologies 2532 
Phospho-AMPK (T172) Cell Signaling Technologies 2531 
ATM (2C1 mAb) GeneTex GTX70103 
Phospho-ATM (S1981) R & D Systems * AF1655 
Phospho-ATM (S1981) Epitomics ** 2152-1 
B-integrin BD Biosciences 610467 
Catalase Abcam ab1877 
Flag (M2) Sigma-Aldrich F3165 
Gamma tubulin (GTU-88 
clone) Sigma-Aldrich T6557 
GAPDH Santa Cruz Biotechnology sc-25778 
Lamin A/C Cell Signaling Technologies 2032 
LC3 Cell Signaling Technologies 2775 
LDH Chemicon AB1222 
LKB1 Cell Signaling Technologies 3050 
Phospho-LKB1(T366) (Dario Alessi Laboratory) (N/A) 
mTOR Cell Signaling Technologies 2972 
Myc Santa Cruz Biotechnology sc-40 
p53 Cell Signaling Technologies 2524 
p62 Santa Cruz Biotechnology sc-28359 
Phospho-p53 (S15) Cell Signaling Technologies 9284 
PMP70 Zymed (Invitrogen) 71-8300 
Rheb Cell Signaling Technologies 4935 
S6 Cell Signaling Technologies 2217 
Phospho-S6 (S235/6) Cell Signaling Technologies 2211 
S6K Cell Signaling Technologies 9202 
Phospho-S6K (T389) Cell Signaling Technologies 9205 
TSC1(5C8A12 mAb) Zymed (Invitrogen) 37-0400 
TSC2 Epitomics 1613-1 
* Used for most of work 
** Used for human cells only 
 
Table 2: List of antibodies used and source
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maintained in Improved Modified Eagle’s Medium (IMEM) supplemented with 10% FBS.  
MCF7 cells stably expressing GFP-LC3 (kindly provided by Dr Gordon Mills, UT MD 
AndersonCancer Center, Houston, TX) were maintained in RPMI 1640 supplemented with 
10% FBS.  Tsc2+/+/p53-/- and Tsc2-/-/p53-/- MEFs (kindly provided by Dr David Kwiatkowski, 
Harvard Medical School, Boston, MA) were maintained in Dulbecco’s MEM (DMEM) 
supplemented with 10% FBS.  ATM-deficient human lymphoblasts (GM01526) and control 
ATM-proficient human  lymphoblasts (GM02184) (both purchased from Coriell Cell 
Repositories) were maintained in RPMI 1640 supplemented with 15% FBS.  HeLa S3 (from 
ATCC) were maintained in F12K supplemented with 10% FBS.  ATR-proficient fibroblasts 
(GM15871) and ATR-deficient fibroblasts (GM18366) were purchased from Coriell Cell 
Repositories, and maintained in Dulbecco’s MEM supplemented with 15% FBS. The HeLa S3 
derived clones expressing wild-type or mutant LKB1 were selected in and maintained in F12K 
supplemented with 800µg/mL G418 and 10% FBS.  HEK 293 cells (kindly provided by Dr 
Yinling Hu, UT MD Anderson Cancer Center, Smithville, TX) were maintained in DMEM 
supplemented with 10% FBS. Primary MEFs were derived from genotype-confirmed Atm+/+, 
Atm+/- and Atm-/- embryos at about E13 and maintained in DMEM supplemented with 10% 
(15% for the Atm-/- lines) FBS and 1X pen-strep.  Hela cells (kindly provided by Dr Mark 
Bedford UT MD Anderson Cancer Center, Smithville, TX) were maintained in Eagle’s MEM 
supplemented with 10% FBS.  SKOV3 ovarian carcinoma cells (kindly provided by Dr Gordon 
Mills, UT MD Anderson Cancer Center, Houston, TX) were maintained in RPMI 1640 
supplemented with 10% FBS.  Vector and ATG5-shRNA transfected SKOV3 clones were 
generated by a standard protocol allowing clonal selection and expansion in McCoys 5A 
media supplemented with 10% FBS, 0.5µg/mL puromycin and 2mM L-Glutamine (Invitrogen, 
Carlsbad, CA), which was kept constant during experiments. 
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2.3 Plasmids 
All of the plasmids I used apart from wild-type and mutant LKB1 were previously available in 
the laboratory.  Full length TSC2 and TSC1 cDNAs were subcloned into pCMV-Tag2 as 
reported in (72).  Mutants of TSC2 were generated by site-directed mutagenesis using the 
Stratagene (Austin, TX) Quikchange II Kit. The AMPK2A mutant contains alanine substitutions 
at Thr 1271 and Ser 1387.  Human Rheb was subcloned by PCR from GST-Rheb into pCMV-
Tag3B to generate a Myc-tagged construct.  Hemagglutinin (HA)-tagged S6K was kindly 
provided by Dr John Blenis (Harvard Medical School, Boston, MA).  Histidine-tagged LKB1 
was kindly provided by Dr Ming-Hui Zou (University of Oklahoma Helath Science Center, 
Oklahoma City, OK). All of the constructs were sequenced for validation prior to using for 
experiments. 
 
2.4 Measurement of ROS by 5-6-chloromethyl-2’,7’-dichlorohydrofluorescein (CM-H2-
DCFDA) 
Cells were trypsinized from plates and counted.  Equal numbers of cells (usually 250,000 cells 
per well) were placed into wells (n=3-6) of a black-bottomed 96-well plate and centrifuged at 
1000 rpm for 10 minutes.  The cells were then resuspended in the cell-permeable dye, CM-H2-
DCFDA [(Invitrogen, (Carlsbad, CA)] at a concentration of 10µM (dissolved in DMSO and then 
1X PBS).  The plate was incubated at 37°C for 30 minutes in the dark, since DCFDA is light-
sensitive.  The resulting fluorescence which is proportional to the amount of ROS in the cells 
(130) was measured with a Synergy HT Multidetection Microplate Reader (BioTeK Instruments 
Inc, Winooski, VT) at an excitation wavelength of 485/10nm and an emission wavelength of 
528/20nm. 
 
2.5  Western Blots 
Cell lysates were prepared for SDS-PAGE by scraping into lysis buffer [20mM Tris HCl 
(pH7.5), 150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1% Triton X-100, 2.5mM Na2P2O7 and 
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1mM β-glycerophosphate]. The following inhibitors were added to individual aliquots of buffer 
immediately prior to being added to cells and the unused portion was discarded: 1mM 
phenylmethylsulfonyl fluoride, 1mM Na3VO4, 1mM NaF and 1X protease inhibitor cocktail 
(Roche, Indianapolis, IN). 
 Protein concentration was determined using the Pierce BCA assay (Thermo Fisher 
Scientific, Rockford, IL) and typically 30µg of total protein was loaded per lane.  The BioRad 
(Hercules, CA) Criterion precast gel system was utilized for western blots  performed by 
standard methods.  For experiments requiring quantitation, films were scanned manually and 
densitrometry performed using ImageQuant software. For signaling studies requiring 
normalization, the phosphorylated protein density was divided by the total protein density, and 
the control was set to 1. 
 
2.6 siRNA transfection 
Chemically synthesized siRNA SMARTpools were obtained from Dharmacon (Thermo Fisher 
Scientific, Rockford, IL).  The catalog numbers of the each siRNA pool ordered are: 
• Human TSC2: M-003029-02 
• Human ATM: L-003201-00-05 
• Human ATR: L-003202-00 
• Human LKB1: L-005035-00 
• Human p53: M-003329-01 
• Negative control/RISC-free: D-001220-01 (contains at least four mismatches to all 
known human, mouse and rat genes) 
The oligonucleotides were resuspended in 1X buffer (Dharmacon) to a stock concentration of 
20µM. 
 MCF7 cells were plated in 35mm plates approximately 36 hours prior to transfection. 
The stock concentrations of siRNA were diluted 1:100 in 1X buffer (making a final 
concentration of 10nM), and DharmaFECT1 transfection reagent was diluted 1:50 in OptiMEM 
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medium (Invitrogen, Carlsbad, CA).  The diluted siRNA and diluted DharmaFECT were then 
incubated for 30 minutes at room temperature in a 1:2 ratio in a total volume of 600µL.  The 
cells were washed with OptiMEM and regular IMEM medium was replaced to a total volume of 
4mL plate (accounting for the 600µL of transfection master mix to be added).  Knockdown 
efficiency was determined by western analysis at 48 hours after transfection; and hydrogen 
peroxide or DNA damaging agents were added as indicated in the figure legends. 
 
2.7 Immunoprecipitation 
HEK 293 cell lysates were prepared in lysis buffer as described in the previous section.  Equal 
masses were aliquoted into tubes and made up to 300µL with PBS, precleared for 1 hour with 
protein A agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA).  After spinning down, 
the supernatant was incubated with LKB1 antibody at 1:100 dilution using a fresh aliquot of 
protein A beads overnight.  After 3 washes with lysis buffer containing protease and 
phosphatase inhibitors as described previously, samples were boiled and loaded directly into 
gels. 
 
2.8 TSC2 functional assay 
HEK 293 cells were plated approximately 24 hours prior to transfection in 6-well plates to be 
60-70% confluent at transfection.  Mastermixes were made containing 3.3µg Flag-TSC2, 
0.9µg Flag-TSC1, 0.4µg Myc-Rheb and 0.4µg HA-S6K DNA in OptiMEM and 10µL 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). 
 
2.9 Subcellular fractionations  
Cytoplasm and nuclear fractions were performed as described in (131).  Briefly, cells were 
scraped into ice-cold hypotonic buffer [10mM HEPES (pH 7.2), 10mM KCl, 1.5mM MgCl2, 
0.1mM EGTA], dounced in a dounce homoegenizer prior to centrifugation at 3,000rpm for 10 
minutes in the cold room.  The supernatant was collected as the cytoplasmic fraction, and the 
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pellet was re-dounced into hypotonic buffer to break up any remainins cells, and re-
centrifuged.  The pellet was the then washed three times in nuclear washing buffer [10mM Tris 
HCl (pH 7.4), 0.1% NP-40, 0.05% sodium deoxycholate, 1.5mM MgCl2] and the nuclei 
extracted by incubation in ice-cold high-salt lysis buffer [20mM HEPES (pH 7.4), 0.5M NaCl, 
0.5% NP-40, 1.5mM MgCl2] for 2 hours in the cold room.  The insoluble material was 
centrifuged out, and the supernatant removed into clean tube as nuclear fraction. 
 For the studies described in chapter 5, a modified protocol for isolating cytoplasmic, 
nuclear and membrane fractions was performed as described in (72). 
 Peroxisome fractionation was performed using the Peroxisome Isolation Kit from 
Sigma-Aldrich (St. Louis, MO) according to the manufacturer’s instructions except that the 
volumes of the reagents were halved because our ultracentrifuge columns were too small to fix 
the entire volume as described in the manual. 
 
2.10 GFP-LC3 localization 
MCF7 cells stably transfected with GFP-LC3 were plated on Labtek II chamber slides and 
allowed to equilibrate for 24 hours.   Cells were exposed to vehicle, rapamycin, or H2O2 for 1 
hour and fixed for 10 minutes in 1:1 acetone/methanol.  Coverslips were mounted using 
Prolong Gold antifade reagent (Invitrogen, Carlsbad, CA) and stored at -20°C until use. 20X 
images were captured using the panoramic setting on a Zeiss confocal microscope.  Images 
were analyzed manually for presence of greater than 5 puncta per cell.  Data is represented as 
puncta positive cells normalized to total number of GFP positive cells. 
 
2.11 Electron microscopy studies 
Cells were plated in 6-well plates and treated as indicated.  After treatment, cells were rinsed 
with 0.1M sodium cacodylate buffer (pH 7.3) twice at room temperature, then fixed in fixation 
buffer containing 2% paraformaldehdyde, 3% glutaraldehyde in 0.1M sodium cacodylate for 1 
hour and stored at 4°C until setup for imaging by the electron microscopy core facility. 
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2.12 Animal studies 
The care and handling of mice were in accordance with National Institute of Health guidelines 
and Association for the Accreditation of Laboratory Animal Care-accredited facilities, and all 
protocols involving the use of these animals were approved by the MD Anderson Animal Care 
and Use Committee.  Atm+/+, Atm+/- and Atm-/- mice on a pure 129 background were 
maintained on-site, on a 12-hour light/dark cycle as described in (132).  For experiments 
involving starvation, the animals were kept overnight without food, but allowed water ad libitum 
throughout.  Rapamycin treatment was performed by daily intraperitoneal injection of 200µL, 
equivalent to a dose of 15mg/kg, with TPE (Tween-80, polyethylene glycol and ethanol used 
as vehicle.   
 For histology sections, tissues were fixed for 24 hours in 10% neutral buffered formalin, 
prior to being stored in 70% ethanol before paraffin embedding, sectioning and staining by the 
UT MD Anderson Cancer Cancer Histology and Tissue Processing core facility on site.  
Sections were stained with hematoxylin and eosin to identify pathological features, and 
immunohistochemistry was performed using phospho-S6 (Cell Signaling Technology, 
Danvers, MA), p53 (Oncogene Science, Cambridge, MA), or Ki67 (Cell Signaling Technology, 
Danvers, MA) antibodies.   
 
2.13 Immunofluorescence 
Hela cells were plated onto chamber slides 18-24 hours before transfection with the indicated 
plasmids. At about 24 hours after transfection, the cells were fixed with 4% paraformaldehyde 
(in PBS) for 10 minutes, washed and stained by standard protocol as described in (131).  
 
2.14 Peroxisomal protease assay 
Protease protection was performed as described in (133).  Briefly, crude peroxisome fraction 
was equally distributed to tubes containing freshly prepared proteinase K (Roche, Indianapolis, 
IN) at a final concentration of 100µg/mL. As a control, whole cell lysate in 1X lysis buffer was 
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used to monitor protease digestion over the incubation time. Samples were then split into two 
groups, one with 1% Triton X-100, and incubated on ice for 5, 10 or 30 minutes.  Reactions 
were stopped by addition of PMSF and immediately processed for western analysis. 
 
2.15 Cell growth assays 
Cells were plated at 30,000 cells per well in 6-well plates approximately 24 hours prior to 
treatment.  On the day of treatment, the media was aspirated and fresh media containing 
cisplatin or vehicle (0.9% NaCl) was added.  After 48 hours of incubation the cells were 
counted using a coulter counter and cell number recorded. 
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Identification of ROS induced activation of cytoplasmic ATM signaling pathway to 
activate LKB1, AMPK and TSC2 to repress mTOR and induce autophagy 
 
3.1 Introduction 
ATM has been postulated to play a role in oxidative stress responses due to the finding that in 
ATM-deficient cells, high levels of ROS exist.  Dysregulation of ROS in these cells has been 
linked to disease etiology both in lymphomagenesis as well as neurodegeneration.  However, 
the underlying mechanism of how ATM acts as a ROS sensor and signals to other proteins as 
part of this oxidative damage response is not well characterized.  Similarly, TSC2 deficient 
cells have been shown to possess elevated ROS, but the mechanism is unclear.  These 
findings led us to ask whether ATM and TSC2-deficiency leads to elevated ROS via a similar 
pathway or not. 
 While our study did not set out to characterize an ATM-dependent stress response, we 
found a novel mechanism by which a specific cytoplasmic pool of ATM could signal to mTOR 
to induce autophagy.  During our work however, additional mechanisms of ROS-induced 
autophagy have been identified as described in the introductory chapter. 
 The main focus of our lab over the recent years has been characterizing the functions 
of the TSC2 tumor suppressor.  Our interest in the role of this protein in stress/damage 
responses was peaked by a report that activation of the p53 transcription factor, which occurs 
in response to many damaging agents, resulted in mTORC1 suppression and subsequent 
induction of autophagy (134). Since up until a few years ago, TSC2 was thought to be the 
primary cellular gatekeeper of mTORC1 activity, we hypothesized that TSC2 activation would 
mediate mTORC1 suppression by DNA damage, and possibly oxidative stress as well, since 
oxidative-induced damage of DNA could lead to p53 activation (105).  
 The pathway we found involves ATM phosphorylation of LKB1, which results in AMPK 
activation and TSC2 activation to repress mTORC1 and induce autophagy.  Importantly, unlike 
the previously identified DNA damage pathway, this ROS-induced signaling pathway does not 
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require p53 activity.  In chapter 6 I will elaborate further on DNA damage-induced signaling 
pathways resulting in mTORC1 suppression. 
 
3.2 Results 
3.21 Confirmation of elevated ROS levels in ATM and Tsc2-deficient cells 
To optimize the protocol for measuring ROS levels using the fluorescent dye, 5-,6-
chloromethyl-2’7’-dichlorodihydrofluorescein diacetate (CM-H2-DCFDA) in cultured cells, we 
obtained immortalized human lymphoblasts from AT-patients and control non-AT-patients to 
establish conditions where we could reproducibly detect differences between these cell lines.  
Figure 8 shows that ROS levels are increased by 2.6 fold in ATM-deficient cells versus ATM-
expressing control cells (p<0.05).  Similarly, we confirmed the earlier finding that TSC2-
deficiency results in elevated ROS (figure 9) using Tsc2-proficient and Tsc2-deficient MEFs, 
which were on a p53-deficient background since p53-inhibition is required to establish long-
term proliferating cultures of these cells to override strong p53- and p21-dependent cellular 
senescence program (135).   
To determine whether this common phenotype between ATM and Tsc2-deficient cells 
occurred as a result of a single downstream pathway, we utilized an siRNA approach where 
we reduced the expression of either ATM, TSC2 or both simultaneously, and measured the 
resulting ROS levels.  Figure 10 shows that loss of both ATM and TSC2 does not further 
increase the ROS level beyond loss of either gene alone, showing that these genes are 
epistatic. 
 The next question we asked was whether elevated ROS in these cells was mTORC1-
dependent, so we treated both sets of cell lines with 200nM rapamycin or vehicle control 
(DMSO), a selective mTORC1-inhibitor overnight, and measured the ROS levels in the cells.  
Figures 11 and 12 show that rapamycin could rescue the elevated ROS levels in both Tsc2-
deficient and ATM-deficient cells.  These results therefore place the ATM-TSC2 pathway at a 
critical point in a feedback loop between ROS levels and mTORC1 activity (figure 13).
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Figure 8: 
 
 
 
Figure 8: Confirmation of elevated ROS in ATM-deficient cells ATM proficient (GM02184) 
and ATM-deficient (GM01526) lymphoblasts were plated 24 hours prior to measurement of 
ROS by DCFDA method.  Graph represents normalized values from 3 independent 
experiments, with 4 wells per cell line. The asterisk signifies statistical significance using one-
sided students t-test (p<0.05). [(Reprinted from (146)] 
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Figure 9: 
 
 
Figure 9: Confirmation of elevated ROS in Tsc2-deficient cells Tsc2 proficient (Tsc2+/+, 
p53-/-) and Tsc2-deficient MEFs (Tsc2-/-, p53-/-) were plated 24 hours prior to measurement of 
ROS by DCFDA method.  Graph represents normalized values from 3 independent 
experiments, with 3 wells per cell line. The asterisk signifies statistical significance using one-
sided students t-test (p<0.05). [(Reprinted from (146)] 
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Figure 10: 
 
 
 
Figure 10: ATM and TSC2 are epistatic in oxidative stress response MCF7 cells were 
transfected with the indicated siRNAs 48 hours prior to measurement of ROS by DCFDA 
method.  Graph represents normalized values from 4 wells per cell line.  
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Figure 11: 
 
 
 
Figure 11: Rapamycin rescues elevated ROS levels in Tsc2-deficient MEFs. Tsc2 
proficient (Tsc2+/+, p53-/-) and Tsc2-deficient MEFs (Tsc2-/-, p53-/-) were plated 24 hours prior to 
treatment with vehicle (DMSO) or 200nM rapamycin. ROS levels were measured by DCFDA 
method after 24 hours of treatment.  Graph represents normalized values from 3 independent 
experiments, with 4 wells per cell line. The asterisk signifies statistical significance using one-
sided students t-test (p<0.05). [(Reprinted from (146)] 
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Figure 12: 
 
 
 
 
Figure 12: Rapamycin rescues elevated ROS levels in ATM-deficient lymphoblasts ATM 
proficient (GM02184) and ATM-deficient (GM01526) lymphoblasts were plated 24 hours prior 
to treatment with vehicle (DMSO) or 200nM rapamycin. ROS levels were measured by 
DCFDA method after 24 hours of treatment.  Graph represents normalized values from 3 
independent experiments, with 4 wells per cell line. The asterisk signifies statistical 
significance using one-sided students t-test (p<0.05). [(Reprinted from (146)] 
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Figure 13: 
 
 
 
Figure 13: Feedback model for the role of ATM and TSC2 in coordinately regulating 
mTOR and ROS levels 
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3.2.2 ROS induced mTOR suppression 
In the previous section, an ROS-mTORC1 feedback loop was established.  To begin 
mechanistic studies into this phenomenon, we asked whether mTORC1 repression would 
occur in cells treated with ROS-generating agents.  For most of these studies, we utilized 
hydrogen peroxide (H2O2) as a tool compound due to the fact that it is membrane permeable 
and readily diffusible into cells.  While hydrogen peroxide is does not contain unpaired 
electrons itself, it can be readily converted into more aggressive radical species such as the 
hydroxyl radical either via exposure to ultraviolet light, or more commonly in vivo, via the metal 
ion-catalyzed Fenton reaction (e.g. Fe2+).  A technical difficulty that we had to overcome during 
these experiments was that upon storage the efficacy of H2O2 decreased for reasons that we 
could not determine, after making sure the bottle was stored in the dark at 4 degrees. 
However, we found that purchasing this chemical freshly approximately once a month 
improved the consistency with which could successfully activate this pathway. 
 MCF7 cells were treated with increasing doses of H2O2 as shown in figure 14 for 1 
hour, and mTOR signaling was analyzed by western blot.  In a dose-dependent manner, both 
S6K and S6 phosphorylation are decreased.  Similarly, in figure 16, we demonstrate that 
mTORC1 activity can be repressed within 30-60 minutes of treatment.  
 To determine whether mTORC1 suppression occurs in response to other agents that 
generate endogenous ROS, MCF7 cells were treated with the mitochondrial uncoupler, 
menadione as well as the phenylethylisothiocyanate (PEITC), which is a natural compound 
that depletes glutathione (which is an antioxidant enzyme).  In addition, the chemotherapeutic 
drug, doxorubicin was used, since it not only generates DNA damage via intercalating into the 
DNA but also generates significant ROS which is thought to be the primary reason that it 
causes cardiac damage in vivo (136).  Figure 15 shows that these other agents that generate 
endogenous ROS also potently and rapidly repress mTORC1 signaling in MCF7 cells. 
To link mTORC1 suppression by hydrogen peroxide specifically to ROS, we utilized 2  
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Figure 14: 
 
 
 
 
 
Figure 14: Dose-response showing mTORC1 suppression by H2O2. MCF7 cells were 
treated with the indicated doses of H2O2 for 1 hour. Lysates were subjected to western 
analysis with the antibodies indicated. 
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Figure 15: 
 
 
 
 
 
Figure 15: mTORC1 is repressed by endogenous ROS MCF7 cells were treated with:  (A) 
doxorubicin for 24 hours, (B) 100 µM menadione for 1 hour or (C) PEITC as indicated. Lysates 
were subjected to western analysis with the antibodies indicated. [(Reprinted from (146)] 
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Figure 16: 
 
 
 
 
 
Figure 16: Time-course showing mTORC1 suppression by H2O2. MCF7 cells were treated 
with the 0.4mM H2O2 for the time periods shown. Lysates were subjected to western analysis 
with the antibodies indicated. 
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ROS scavengers, N-acetyl cysteine (NAC) and catalase.   MCF7 cells were pre-treated with 
3mM NAC or 2950 units of bovine catalase for 1 hour, then challenged the cells with H2O2 for 
an additional 1 hour.  Figure 17 shows that both these scavengers effectively block mTORC1 
repression. 
 
3.2.3 Role of ATM in ROS-induced mTOR repression 
Since we hypothesized that ATM functions as an ROS sensor, we examined whether ROS 
induces ATM activation, as measured by phosphorylation of ATM at Ser 1981, and 
phosphorylation of Chk2 at Thr 68, a well-characterized ATM substrate.  Figure 18 shows that 
ATM is activated in MCF7 cells in response to increasing doses of H2O2. 
To determine whether ATM is required for mTORC1 suppression by ROS, we took 3 
approaches.  Firstly we compared the magnitude of mTORC1 suppression in ATM-proficient 
and ATM-deficient human lymphoblasts.  Figure 19 shows a small, but reproducible difference 
in the ability to repress mTORC1 signaling under conditions of oxidative stress.  When these 
cells were maintained in culture for several weeks however, even the ATM-proficient (WT-B) 
cells became non-responsive to ROS, for reasons we cannot explain.  Importantly these cell 
lines were generated via Epstein-Barr virus-mediated transformation of primary B-
lymphoblasts.  To rule out in vitro immortalization as an inhibitory factor in our experiments, we 
isolated primary mouse-embryonic fibroblasts (MEFs) from Atm+/+, Atm+/- and Atm-/- mice at 
approximately day 13 of development and performed similar studies on multiple clonal isolates 
from these cells.  Figure 20 demonstrates that both Atm wild-type and heterozygous cell lines 
had equivalent responses to H2O2, however the cells lacking Atm had significantly attenuated 
responses (p<0.05).  We confirmed these results in MCF7 cells using siRNA targeting ATM, 
and showed that when ATM is depleted, the ability to suppress S6K phosphorylation is 
decreased, as seen in figure 21.  In contrast to ATM, we showed in figures 22 and 23 that ATR 
is not required for mTORC1 suppression by ROS, using ATR-deficient fibroblasts from a 
Seckel syndrome patient and siRNA targeting ATR.
49 
Figure 17: 
 
 
 
 
 
 
Figure 17: Antioxidant treatment rescues mTORC1 suppression by ROS. MCF7 cells were 
pre-treated with (A) 3mM NAC or (B) 2950 units of bovine catalase for 1 hour prior to 
treatment with H2O2 as shown. Lysates were subjected to western analysis with the antibodies 
indicated. [(Reprinted from (146)] 
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Figure 18: 
 
 
 
 
 
 
Figure 18: Activation of ATM by ROS. MCF7 cells were treated with increasing doses of 
H2O2 as shown. Lysates were subjected to western analysis with the antibodies indicated. 
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Figure 19: 
 
 
 
 
 
Figure 19: Role of ATM in mediating signaling to mTORC1. ATM proficient (“WT-B” - 
GM02184) and ATM-deficient (“AT-B” - GM01526) lymphoblasts were plated 24 hours prior to 
treatment with 0.4mM H2O2 for 1 hour, and lysates were analyzed by western blotting. 
[(Reprinted from (146)] 
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Figure 20: 
 
 
 
 
 
Figure 20: mTORC1 suppression in primary mouse embryonic fibroblasts.  Mouse 
embryonic fibroblasts were generated from Atm+/+, Atm+/-, and Atm-/- mice, and treated with 
0.2mM H2O2 for 1 hour. The graph represents densitometric quantitation of the magnitude of 
suppression of S6K phosphorylation in multiple clonal isolates from each genotype (n=3 per 
group) and the asterisk signifies statistical significance by one-sided students t-test (p<0.05). 
[(Reprinted from (146)] 
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Figure 21: 
 
 
 
 
 
Figure 21: siRNA validation of ATM participation in signaling to mTORC1.  MCF7 cells 
were transfected with siRNA targeting ATM 48 hours prior to treatment with H2O2 for 1 hour. 
Lysates were analyzed by western blot.  
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Figure 22: 
 
 
 
 
 
Figure 22: ATR is not required for mTORC1 suppression by ROS ATR-proficient 
(GM15871) and ATR-deficient (GM18366) fibroblasts were treated with 0.4mM H2O2 for 1 hour 
and lysates analzyed by western blot. 
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Figure 23: 
 
 
 
 
 
Figure 23: siRNA validation that ATR is not required for mTORC1 suppression by ROS 
MCF7 cells were transfected with siRNA targeting ATR 48 hours prior to treatment with H2O2 
for 1 hour. Lysates were analyzed by western blot. The numbers below S6K represent the 
normalized ratio for phosphorylated S6K/total S6K with the control siRNA untreated being set 
to 1. 
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3.2.4  Role of LKB1 in ATM signaling to mTORC1 
To further investigate the mechanism by which ATM signals to mTORC1, we surveyed the 
literature for known potential ATM substrates that may lie upstream of mTORC1.  One obvious 
potential protein we found during this search was LKB1, which is an upstream kinase for 
AMPK.   LKB1 was previously shown by Dario Alessi’s group to be phosphorylated by ATM in 
response to DNA damage (137).  HeLa S3 cells, which are LKB1-null human cervical 
carcinoma cells, were utilized to establish a correlation between LKB1 expression and 
mTORC1 suppression, and as expected, these cells did not repress mTORC1 in response to 
ROS.  However, stable reconstitution with wild-type LKB1 expression, restored these cells 
responsiveness to ROS.  In contrast, cells reconstituted with an LKB1-construct lacking the 
ATM phosphorylation site did not respond to ROS, meaning that ATM phosphorylation at this 
site is required for signaling to mTORC1. Figure 24 shows the results of signaling analysis in 
representative clones from each construct, and the parental HeLa S3 as a control. 
Direct evidence of LKB1 phosphorylation by ROS was obtained by performing 
immunoprecipitations of endogenous LKB1 and western blotting with a phospho-specific 
antibody generated by and kindly provided by Dario Alessi’s group.  Ionizing radiation was 
used as a positive control for activating this ATM-LKB1 pathway.  As shown in figure 25, both 
H2O2 and ionizing radiation (IR) induce phosphorylation of LKB1 at Thr 366 in HEK 293 cells. 
siRNA knockdown of LKB1 was used as an additional method to show the requirement for 
LKB1 in signaling from ATM to mTORC1.  Depletion of LKB1 results in a quantitative decrease 
in the responsiveness to ROS as seen in figure 25.
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Figure 24: 
 
 
Figure 24: LKB1 reconstitution of HeLa S3 cells and responsiveness to ROS.  (A) 
Western blot showing LKB1 expression in stable clones shown in (B).  (B) Western blot 
analysis of mTORC1 repression in response to ROS. WT represents clone reconstituted with 
wild-type LKB1 and MT represents clone reconstituted with T366A mutant LKB1. (C) Graph 
showing densitometric quantitation of mTORC1 repression in response to 0.4mM H2O2 in all 
clones analyzed (wild-type, n=4; T366A mutant, n=2). The single asterisk represent a 
significant difference versus parental (p<0.03) and the double asterisks represent significance 
compared against wild-type(p<0.05), both using one-sided student’s t-tests. [(Reprinted from 
(146)]
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Figure 25: 
 
 
 
 
Figure 25: LKB1 phosphorylation in response to ROS.  Immunoprecipitation and western 
analysis showing that endogenous LKB1 is phosphorylated in response to H2O2 in HEK 293 
cells. [(Reprinted from (146)] 
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Figure 26: 
 
 
 
 
 
 
Figure 26: siRNA validation of LKB1 participation in signaling to mTORC1.  MCF7 cells 
were transfected with siRNA targeting LKB1 48 hours prior to treatment with H2O2 for 1 hour. 
Lysates were analyzed by western blot. [(Reprinted from (146)] 
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3.2.5 AMPK activation by ROS leads to TSC2 activation 
In the previous section we showed that LKB1 is activated in response to ROS.  We next asked 
whether AMPK was subsequently activated.  Using the MCF7 dose-response lysates 
generated for use in figure 14, AMPK activation was examined.  We observed a dose-
dependent activation of AMPK as shown in figure 27. As further evidence for AMPK activation 
resulting in mTORC1 suppression, we analyzed the kinetics of AMPK activation and mTORC1 
in MCF7 cells.  We observed an extremely rapid activation of AMPK (as measured by 
phosphorylation of acetyl co-A carboxylase, a downstream substrate of AMPK) within 5 
minutes of treatment, whereas S6K phosphorylation took at least 30 minutes to decrease. 
(figure 28). 
 To determine whether AMPK activation is required for mTORC1 suppression by ROS, 
we utilized Compound C (6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-
pyrimidine), an ATP-competitive pharmacological inhibitor of AMPK discovered in a high-
throughput chemical library screen (58).  MCF7 cells were pre-treated with 20µM Compound C 
for 3-12 hours prior to treatment with 0.4mM H2O2 for 1 hour.  Figure 29 shows that Compound 
C blocks the ability to suppress mTORC1 in response to ROS. 
 As the final potential step in the mechanism, we investigated whether AMPK 
phosphorylation of TSC2 is important in mediating mTORC1 repression by ROS.  To answer 
this question, we developed a cellular functional assay in HEK 293 cells.  Flag-tagged TSC2 
and binding partner TSC1 constructs were cotransfected along with the GAP target Rheb 
which was Myc-tagged, and HA-tagged S6K as the mTORC1 substrate and readout.  After 
transfection, cells were treated with H2O2 or left untreated, and phosphorylation of S6K 
analyzed by western blot.  Since HEK 293 cells are very highly transfectable (>90% efficiency 
based on GFP expression), immunoprecipitation of over-expressed S6K was not necessary for 
accurate results.  As figure 30 shows, when wild-type TSC2 is transfected, ROS can induce 
robust mTORC1 suppression, whereas if TSC2 lacking 2 of the major AMPK phosphorylation 
sites is transfected, mTORC1 suppression is significantly decreased.
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Figure 27: 
 
 
 
 
 
Figure 27: AMPK activation by ROS.  MCF7 cells were treated with increasing doses of H2O2 
as indicated and western blots performed as indicated.  These lysates were from the same 
experiment as shown in figure 14. 
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Figure 28: 
 
 
 
 
 
Figure 28: Activation of AMPK prior to mTORC1 suppression.  MCF7 cells were treated 
with 0.4mM H2O2 for the indicated time points, prior to western blots as indicated.  The 
numbers represent normalized densitometric ratios for phosphorylated S6K/total S6K, with the 
first lane being set to 1. [(Reprinted from (146)] 
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Figure 29: 
 
 
 
 
 
 
Figure 29: AMPK inhibition blocks mTORC1 suppression by ROS.  MCF7 cells were pre-
treated with 20µM Compound C for 3-12 hours as indicated, then challenged with 0.4mM 
H2O2. Western analysis shows that inhibition of AMPK with Compound C significantly blocks 
the ability to repress mTORC1. [(Reprinted from (146)] 
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Figure 30: 
 
 
 
 
 
Figure 30: AMPK phosphorylation of TSC2 mediates mTORC1 suppression by ROS.  
Western blots from TSC2 functional assay in HEK 293 cells showing that mutation of AMPK 
phosphorylation sites in TSC2 (TSC2 AMPK 2A) results in attenuated mTORC1 suppression 
by H2O2. [(Reprinted from (146)]
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 To more definitively determine whether TSC2 participates in this signaling pathway, we 
utilized Tsc2-deficient and Tsc2-proficient MEFs, and used siRNA targeted against TSC2 in 
MCF7 cells.  At even the highest concentration of H2O2 tested (which has been our standard 
dose in many of the experiments previously described), MEFs lacking Tsc2 failed to repress 
mTORC1, while the Tsc2-expressing line did possess an intact signaling pathway from ATM to 
mTORC1 as shown in figure 31.  Figure 32 shows that when TSC2 was quantitatively 
decreased using siRNA, we could also see a proportionally diminished response to ROS 
confirming the results in the MEFs previously demonstrated.   
 Since the Tsc2-proficient MEFs we utilized completely lacked p53 expression, and 
could repress mTORC1, we could also rule out a role for p53 in mediating an ATM-dependent 
pathway to mTORC1.  siRNA targeting p53 in MCF7 cells was used to confirm that p53 is not 
required for mTORC1 repression by ROS, as shown in figure 33. 
 
3.2.6  Localization of activated ATM signaling to LKB1 and AMPK 
The mechanism described so far describing ATM as a ROS sensor, and signaling through 
LKB1 and AMPK to activate TSC2 and suppress mTORC1 present an interesting conundurm.  
While TSC2 has not been found to be localized to the nucleus outside of a few isolated reports 
that are not widely accepted in the field (138, 139). ATM has been found both in the nucleus 
and in various cytoplasmic organelles. Detailed studies of the activation status of extranuclear 
ATM have not been performed thoroughly.   Identifying therefore the localization of ROS-
activated ATM and the downstream components of this signaling pathway would further 
elaborate on the mechanism by which mTORC1 is regulated by ROS. 
 To begin to shed light on this question, untreated and H2O2-treated MCF7 cells were 
fractionated into cytoplasmic and nuclear fractions, and western blots were performed to look 
at the distribution of phosphorylated ATM and downstream proteins.  Figure 34 shows that 
while ATM can be phosphorylated by in the cytoplasm and nuclear fractions, LKB1 is only 
expressed in the cytoplasm, and AMPK is also exclusively cytoplasmic.  
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Figure 31: 
 
 
 
 
 
Figure 31: Tsc2 involvement in signaling to mTORC1 in MEF cells. Tsc2-proficient and 
Tsc2-deficient MEFs were treated with 0.2mM or 0.4mM H2O2 for 1 hour, and lysates were 
analyzed by western blot. [(Reprinted from (146)] 
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Figure 32: 
 
 
 
 
Figure 32: Role of TSC2 in signaling to mTORC1 in human cells. MCF7 cells were 
transfected with siRNA targeting TSC2 48 hours prior to treatment with H2O2 for 1 hour. 
Lysates were analyzed by western blot. [(Reprinted from (146)] 
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Figure 33: 
 
 
 
 
Figure 33: p53 is not required for mTORC1 suppression by ROS. MCF7 cells were 
transfected with siRNA targeting p53 48 hours prior to treatment with H2O2 for 1 hour. Lysates 
were analyzed by western blot. [(Reprinted from (146)] 
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Figure 34: 
 
 
 
 
 
Figure 34: Fractionation showing localization of ATM-LKB1-AMPK signaling node. 
Cytoplasmic and nuclear fractions from MCF7 cells treated with 0.4mM H2O2 for the indicated 
times were obtained, and western blots performed showing that although ATM is activated 
both in the cytoplasm and the nucleus, that LKB1 and AMPK are exclusively in the cytoplasm. 
LDH was used as a cytoplasmic marker, and LAMIN is a nuclear marker. [(Reprinted from 
(146)] 
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 Activated ATM in the cytoplasm could be as a result of either activation of a 
cytoplasmic pool of ATM that is distinct from the nuclear pool, or translocation of activated 
ATM from the nucleus, similar to that seen after DNA damage to activate NF-κB.  To 
distinguish between these two possibilities, we utilized leptomycin B, a chemical inhibitor of 
nuclear export.  Firstly we pre-treated MCF7 cells with 100ng/ml leptomycin B for 5 hours and 
asked whether ATM could be activated and mTORC1 inhibited by ROS.  Figure 35 shows that 
leptomycin B had no effect on the ability for ROS to induce ATM activation and mTORC1 
suppression.  Next we performed a similar experiment but fractionated the cells into 
cytoplasmic and nuclear fractions, and as expected saw that the amount of ATM activated in 
the cytoplasm was equivalent in both treated and untreated cells (figure 36).   
 
3.2.7 mTORC1-dependent autophagy regulation by ROS 
The findings so far presented in this chapter have established that a cytoplasmic pool of ATM 
can be activated by ROS to repress mTORC1 signaling.  mTORC1 itself can regulate multiple 
cellular processes, most notably protein synthesis and autophagy.  During our signaling work, 
there was increased interest from the autophagy community regarding how ROS may be a 
physiological regulator of autophagy both under starvation conditions and some tissue-specific 
examples such as ischemia/reperfusion injury in the heart (140, 141).  Therefore, we decided 
to look at whether ROS might regulate autophagy via the ATM-LKB1-AMPK-TSC2-mTOR 
pathway. 
 One of the best characterized experimental approaches for demonstrating the 
autophagy is induced is through use of the LC3 marker by western blot or cellular localization 
using a GFP-tagged construct.  LC3 is the mammalian homolog of the yeast Atg8 protein, and 
is a necessary protein for autophagy induction in yeast (142).  When autophagy is induced, 
LC3 becomes lipidated with the molecule phosphatidylethanolamine, which allows it to 
associate with the newly forming autophagosomal membrane.   This lipidated form runs at a 
higher mobility, and therefore can be observed at an apparently smaller molecular weight 
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Figure 35: 
 
 
 
 
Figure 35: Leptomycin B does not block ATM signaling to mTORC1 in response to ROS. 
MCF7 cells were treated with 100ng/mL leptomycin B or vehicle for 5 hours prior to treatment 
with 0.4mM H2O2 or vehicle for 1 hour.  Whole cell lysates were taken for western analysis as 
shown in this figure. [(Reprinted from (146)] 
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Figure 36: 
 
 
 
 
Figure 36: Equivalent ATM activation in cytoplasmic fraction of leptomycin treated MCF7 
cells. MCF7 cells were treated with 100ng/mL leptomycin B or vehicle for 5 hours prior to 
treatment with 0.4mM H2O2 or vehicle for 1 hour.  Cytoplasmic fractions were isolated for 
western analysis as shown in this figure.  LDH was used as a cytoplasmic marker, and LAMIN 
is a nuclear marker to show lack of nuclear contamination. [(Reprinted from (146)] 
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 on a standard SDS-PAGE gel. 
 We used stably-expressing MCF7 GFP-LC3 cells, kindly provided by Dr Gordon Mills 
laboratory, as well SKOV3 GFP-LC3 cells to show that ROS induces autophagy.  Stable 
transfection of GFP-LC3 is now broadly appreciated to be necessary for accurate results, 
since it has been shown that transient transfection alone is problematic because lipid-based 
transfection reagents such as the commonly used Lipofectamine 2000 induce autophagy both 
with and without DNA (143).  By using stable transfection and making sure experiments were 
not performed within 2 weeks of thawing cells from cryogenic storage, this transient off-target 
induction of autophagy is no longer a confounder.  Cells were plated in chamber slides and 
treated with increasing doses of H2O2, and cells were imaged at 1 hour post-treatment using 
epifluorescence or confocal microscopy. As controls to ensure the system was working we 
also treated cells with rapamycin or vehicle control (DMSO).  To analyze these results, we 
counted the total number of GFP-positive cells, and determined whether the GFP was diffuse 
(ie LC3 was not lipidated) or punctate (lipidated LC3, indicating binding to autophagosomal 
membranes).  Figure 37 shows an example of punctate GFP localization in H2O2 treated cells, 
with an inset showing the baseline diffuse pattern, and the accompanying graph quantifies the 
increase in number of cells with punctate GFP for H2O2 and rapamycin normalized separately 
to their respective controls.  We also performed western analysis on SKOV3 ovarian 
carcinoma cells treated with H2O2 and used rapamycin again as a positive control. Figure 38 
shows that when mTORC1 is suppressed by rapamycin or H2O2, that LC3 II, the lipidated form 
of LC3 is increased relative to total proteins shown for signaling pathway members.  
 Although an increase in LC3 II expression and increased number of punctate GFP-LC3 
dots usually signifies an increase in autophagosome formation, it may also indicate a 
downstream block in the autophagy pathway such as in autophagosome maturation or fusion 
with the lysosome.  In order to rule out these alternative interpretations of the results  
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Figure 37: 
 
 
 
 
Figure 37: GFP-LC3 localization in response to ROS. MCF7 cells stably expressing GFP-
LC3 were treated with H2O2 or Rapamycin as a positive control for induction of autophagy.  
Images were taken of fluorescence localization after 1 hour, and cells were scored either as 
punctate (arrows, represent induction of autophagy) or diffuse (inset image, autophagy not 
induced).  The graph represents the number of punctate cells divided by total GFP positive 
cells, with each of the vehicles set to 1. Asterisks represent significant increases compared 
with the matched vehicle (p<0.0001 χ2 test). [(Reprinted from (146)] 
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Figure 38: 
 
 
 
 
 
Figure 38: Increased LC3 lipidation in response to ROS. SKOV3 cells were treated with the 
indicated doses of H2O2 or DMSO or 400nM rapamycin (Rapa) as a positive control for 
induction of autophagy. Lysates were analyzed by western blot using the indicated antibodies.  
The numbers below the LC3 blot represent normalized densitometric ratios of LC3 II / LC I 
setting the untreated (NT) control to 1. [(Reprinted from (146)]
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presented, we used two complementary approaches.  Firstly, we blocked lysosomal function 
using the lysomotropic drug chloroquine, which neutralizes the positive charge in the 
lysosome, which is necessary for enzymatic degradation of the contents.  Figure 39 
demonstrates that LC3 II could still be increased in the presence of chloroquine, indicative of 
increased autophagic flux and not just a downstream block induced by ROS.  We obtained 
more definitive evidence of increased flux by measuring turnover of p62, since p62 is 
degraded by autophagy – hence if there was a downstream block in degradation, p62 levels 
would not be decreased over time.  Figure 40 shows that p62 is degraded in a time-dependent 
manner in response to ROS. 
 Electron microscopy has been the gold standard for observation of autophagosomes at 
a sub-cellular level for many years now, even though it is rather labor-intensive, not amenable 
to high-throughput analysis or particularly quantitative without specially written software.  
Despite these limitations, we did observe an increase autophagosomes filled with cytoplasmic 
material in cells that were treated with H2O2, as shown in figure 41. 
Taken together we have shown by multiple methods that ROS induces 
autophagosome formation and a subsequent increase in autophagic flux.  Future sections will 
deal with the cellular consequences that this process may play.
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Figure 39: 
 
 
 
 
 
Figure 39: LC3 II accumulation in the presence of chloroquine indicates increase in 
autophagic flux. SKOV3 cells were treated with 100mM chloroquine for 2 hours prior to 
treatment with 0.4mM H2O2 for the indicated times. Lysates were made and analyzed by 
western blots as shown. [(Reprinted from (146)] 
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Figure 40: 
 
 
 
 
 
 
Figure 40: Degradation of p62 in response to ROS. SKOV3 cells were treated with 0.4mM 
H2O2 for the indicated periods of time and lysates analyzed by western blot.  p62 is an 
degraded by autophagy, so it represents a measure of autophagic flux. [(Reprinted from (146)] 
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Figure 41: 
 
 
 
 
Figure 41: Electron microscopy images showing autophagosome increase after ROS 
exposure  The inset is a zoomed in image of an autophagosome filled with cargo.  The 
nucleus is the darker structure on the bottom left side.  The arrows point to autophagosomes. 
[(Reprinted from (146)]
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3.3 Discussion 
In this chapter, we have described the discovery of a novel cytoplasmic signaling pathway 
initiated as a result of ROS activation of ATM, resulting in mTORC1 suppression. This 
pathway contrasts with another recently identified pathway that is engaged in response to 
genotoxic stress to repress mTORC1.  This alternative pathway involves p53-mediated 
induction of sestrin 1 and sestrin 2, which were found to lie upstream of AMPK and TSC2 
(144).  The mechanism we have described is distinct from this due to the requirement for p53 
and the fact that it is redox-independent. 
 In addition to ATM and TSC2, we observed a dependence on LKB1 for mTORC1 
suppression by ROS, which contrasts with an earlier report that in Hela cells, that lack LKB1, 
AMPK could be activated by etoposide in an ATM-dependent manner to regulate 
mitochondrial biogenesis (145).  In this report, AMPK was phosphorylated at Thr 172 which is 
the same phosphorylation site as that which is activated by LKB1, indicating that there are 
multiple routes to the same outcome.  On a mechanistic level however, activation of AMPK by 
etoposide required prolonged treatment, in contrast to the very fast activation of AMPK by 
ROS, again underscoring that multiple pathways exist to regulate AMPK and mTORC1 that 
may be differentially engaged based on the type of damage, dose and perhaps in a cell-type 
dependent manner. 
 Prior to our report (146), the function of the ATM phosphorylation site on LKB1 (Thr 
366) had been somewhat elusive.  In G361 melanoma cells which lack endogenous LKB1 
expression, reconstitution with a T366A mutant LKB1 was threefold less efficient at 
suppressing cell growth when compared to wild-type LKB1 (147).  Our data support this claim 
that ATM phosphorylation of LKB1 is important functionally, since AMPK could not be 
activated in response to ROS in the stable cell lines expressing the T366A mutant LKB1.  
Although LKB1 activation of AMPK via phosphorylation has been well-documented for many 
years, its function as an obligate kinase for AMPK is still controversial.  In LKB1 deficient cells 
such as HeLa or Lkb1-/- MEFs, AMPK is not activated by classical agonists such as AICAR or 
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metformin, however AMPK can still be activated and basally phosphorylated at Thr 172 in 
these cells, suggesting that other AMPK kinases can compensate to regulate the key 
metabolic processes that are controlled by AMPK (148).  
 Although we have shown through various approaches that there is an ATM and TSC2-
dependent signaling pathway to regulate autophagy in response to ROS, we cannot exclude 
additional pathways that are independent of ATM and TSC2, especially at higher 
concentrations of H2O2 and/or at later time points.  In figure 23, the slight repression of 4E-BP1 
phosphorylation at the highest dose (0.4mM) suggests that perhaps a portion of mTORC1 is 
being inhibited even in the absence of Tsc2.  In addition, the TSC2 functional assay suggests 
that expression of the mutant lacking the AMPK phosphorylation sites was only partially 
inactive in the ROS response. One potential explanation for the small amount of mTORC1 
suppression in Tsc2-deficient cells is based on the fact that AMPK is constitutively active in 
these cells (149, 150).  AMPK was shown a few years ago to phosphorylate raptor, a 
component of the mTORC1 complex, in response to energy stress to inhibit cell growth, as a 
survival measure (151). It is plausible therefore that when AMPK is activated by ROS that 
raptor phosphorylation also increases which induces binding to 14-3-3 and inactivation of the 
mTORC1 complex kinase activity.  This hypothesis could be tested with the newly 
commercially available phospho-specific antibodies to the raptor phosphorylation sites. 
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In vivo study of mTOR signaling in Atm-deficient mice 
 
4.1 Background into Atm knockout mouse model 
Atm deficient mice have been developed as an in vivo model to understand the etiology of 
ataxia telangiectasia.  However, beyond this rare disease, somatic ATM mutations have been 
found in other human cancers including breast and ovarian cancers (152), and T-
prolymphocytic leukemia, a rare malignancy that occurs in both AT-patients and AT-carriers 
who lose ATM function due to rearrangements or point mutations (153). These mice therefore 
have the potential to teach us more general principles about cancer as well as AT-specific 
concepts. 
 Atm deficient mice recapitulate most of the phenotypes of the human disease including 
the significant propensity to develop hematologic malignancies, however the 
neurodegeneration phenotype is much less pronounced, for reasons that are still not clear.  
Homozygous knockout mice develop aggressive immature T-cell thymic  lymphoblastic 
lymphomas at an early age, and these tumors are the usual cause of mortality by 3-4 months 
of age from compression of the heart and lungs or even metastases (or both) (132). The 
tumors are though to arise from clonal expansions of CD4/CD8 double positive thymocytes 
that possess translocations involving chromosomes 12 or 14 near the T-cell receptor loci, 
similar to the cytogenetic characteristics seen in the lymphoid tumors in humans. 
 In addition to the cancer predisposition phenotype, the homozygous knockout mice 
have several other important phenotypes.  At the gross level, these mice are growth retarded 
by 10-25% in comparison to age- and sex-matched littermates, and this persists into 
adulthood.  Development of mouse embryonic fibroblast cell lines from these animals is a 
challenge since they proliferate very slowly and become senescent within only a few passages 
to the rapid accumulation of DNA damage which activates p53 and p21 to induce growth 
arrest.   When we attempted to isolate these cells, we found that maintaining the cells in 15% 
FBS prolonged their survival. 
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 The accumulation of DNA damage in Atm-deficient cells also contributes to infertility.  
Although the mice possess grossly normal reproductive organs, the gonads are extremely 
small and completely lack mature gametes. This is because there is an early meiotic arrest 
due to abnormal chromosomal synapsis causing chromosomes to become broken and induce 
apoptosis. 
 Atm appears to be important in normal T-cell development in vivo.  Atm-knockout mice 
have significantly decreased numbers of thymocytes, resulting in an overall hypoplastic 
thymus (132).  Immature B-cells in the bone marrow are also negatively impacted by Atm loss, 
however mature peripheral B cells are not affected suggesting that other pathways can 
compensate during later development (132). 
 As expected, the Atm-deficient mice are also highly radiation sensitive.  When the 
knockout mice were challenged with ionizing radiation at a dose sufficient to kill two-thirds of 
wild-type and heterozygous mice within 6-18 days of exposure (8 Gy), these mice died in only 
3-5 days due to acute gastrointestinal tract toxicity as opposed to a global radiation toxicity 
involving the immune system (which happens to both the wild-type and mutant mice). 
 One of the surprises in this model however is the relatively weak neurological defects 
seen.  The mice perform more poorly on tests of motor function, but at first there was little 
histological evidence of neurodegeneration, leading to the hypothesis that since the 
development of neurodegeneration in humans occurs later in life, the mice succumb to 
malignancy too early in life to develop overt degenerative features.  Upon further detailed 
studies by a different group however, a subtle neuronal degeneration was observed by 
electron microscopy analysis of granule cells, Purkinje neurons and molecular layer neurons in 
the cortex (154).  Several years after being generated, several new interesting aspects of 
neuronal physiology in these animals were uncovered.  In the absence of detectable neuronal 
degeneration, Carrolee Barlow et al, observed an increased in the number of lysosomes in 
Purkinje neurons using electron microscopy in Atm knockout mice relative to wild-type controls 
(155). Also reported in this study was the fact that ATM is exclusively cytoplasmic in Purkinje 
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neurons and some dorsal root ganglion cells in these mice (similar to what has been reported 
in adult human cerebellum) suggesting that loss of ATM may impact the autophagic-lysosomal 
system in multiple ways in vivo. 
 
4.2 Rationale for study 
Once we uncovered the signaling pathway described in the previous chapter, we wanted to 
study the in vivo relevance of the dysregulation of the oxidative stress-mTORC1-autophagy 
pathway.  We performed studies to investigate: 
(a) whether mTORC1 signaling was dysregulated in Atm-deficient mice and if so, 
(b) whether targeting this abnormality with rapamycin could rescue lymphomagenesis and 
prolong survival. 
 
4.3 Results 
4.3.1 Analysis of mTORC1 signaling and AMPK activation in Atm-mouse model 
We began our investigations of mTORC1 pathway activity by studying various normal tissues 
(including the front and hind brain, liver, kidneys, thymi, cardiac and skeletal muscle) from 
adult Atm+/+, Atm+/- and Atm-/- mice (2-3 months of age).  This approach gave us very mixed 
results, with the first batch of animals taken showing a trend for elevated mTORC1 activity in 
the Atm-/- mice, however, upon validation with a larger cohort of animals, we did not see this 
correlation.  Also of relevance was that the animals were sacrificed at different times of the day 
which may have had some impact on signaling due to the time of last feeding. In the literature, 
evidence for wide-spread significant signaling abnormalities in normal tissues from knockout or 
transgenic mice is generally lacking, perhaps due to issues similar to this where inter-animal 
variability due to feeding, physical activity or other factors makes analysis of mTORC1 activity 
too challenging. 
What was consistent from our studies however was that in the older animals, some of 
which were already developing lymphomas, mTORC1 signaling was elevated in the thymus.  
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Upon setting up the survival study described below, when we analyzed the tumors from the 
moribund animals we confirmed that lymphomas possess elevated mTORC1 signaling. Figure 
42 shows a representative sample of thymi and lymphomas that were analyzed by western 
blot.  Figure 43 shows quantitation from a larger panel of tissues using both phospho-S6K and 
phospho-S6 levels as measures of mTORC1 activity. 
Next we analyzed AMPK activation based on the hypothesis that loss of Atm would be 
predicted to cause elevated ROS, but without Atm expression, AMPK would not be activated.  
Our findings as shown in figures 44 and 45 demonstrate that the lymphomas possessed 
decreased AMPK activity compared to normal thymi, consistent with elevated mTORC1 
activity, and lack of signaling from ATM to LKB1 and AMPK. 
 
4.3.2 Response of lymphomas to rapamycin 
The discovery of dysregulated mTORC1 signaling in Atm-deficient lymphomas, raised the 
question of whether rapamycin or other mTOR-targeted therapeutics would be efficacious in 
killing these tumors.  To study the responses of Atm-deficient lymphomas to rapamycin, we 
performed two related experiments.  In the first study, we administered rapamycin at a dose of 
15mg/kg by intraperitoneal injection daily for 7 days to adult mice approximately 3 months of 
age and sacrificed the animals 2 hours after their last dose. To try to control for food intake, we 
took some of the animals and starved them overnight (but water was available ad lib for all 
animals).  Ultimately however the effects of rapamycin were equally strong in both treatment 
protocols.  Figure 46 demonstrates our findings at the histological level in this short-term 
study, performed with the assistance of our on-campus veterinary pathologist.  While the 
lymphomas from the vehicle treated mice are large and composed of solid sheets of uniform 
neoplastic cells, the rapamycin-treated sections show dramatic tumor shrinkage and some 
suggestion of normal thymic architecture.  As expected, rapamycin significantly decreases the 
number of phospho-S6 positive cells. In addition, these treated tumors express decreased 
p53, Ki67 (indicative of proliferation) and TUNEL (indicative of apoptosis).  
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Figure 42: 
 
 
 
 
 
 
Figure 42: mTORC1 activity is elevated in lymphomas from Atm-/- mice. Normal thymus 
from Atm+/- mice and lymphomas from Atm-/- mice were analyzed by western blotiing for 
mTORC1 activity in both mice that were allowed to feed ad lib, and mice starved from food 
overnight, and treated with rapamycin or vehicle as indicated. 
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Figure 43: 
 
 
 
 
Figure 43: Quantitation of mTORC1 elevation in lymphomas from Atm-/- mice. Graphs 
represent densitometric analysis of phosphorylated S6/total S6 or phosphorylated S6K/total 
S6K in ad lib fed mice.  For the S6 graph the sample sizes were: n=7 normal thymus, n=12 
tumors and n=6 tumors+rapa. For the S6K graph the sample sizes were n=5 normal thymus, 
n=9 tumors and n=4 tumors+rapa. The asterisk means p<0.05 (Mann-Whitney test) versus 
normal thymus and the double asterisks means p<0.05 versus the tumor. [(Reprinted from 
(146)] 
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Figure 44: 
 
 
 
 
Figure 44: AMPK is not activated in Atm-/- mice. AMPK phosphorylation was analyzed by 
western analysis in normal thymus from Atm+/- mice and lymphomas from Atm-/- mice.  Despite 
elevated ROS in the lymphomas as a result of Atm loss, AMPK is not phosphorylated, 
consistent with requirement for Atm in this pathway. 
89 
Figure 45: 
 
 
 
 
Figure 45: Quantitation of AMPK activation in Atm-/- mice. Graphs represent densitometric 
analysis of phosphorylated AMPK/total AMPK in ad lib fed mice.  For the S6 graph the sample 
sizes were: n=3 normal thymus, n=4 tumors. The asterisk means p<0.05 (Mann-Whitney test) 
versus normal thymus. 
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Figure 46: 
 
 
Figure 46: Histological characterization of response to rapamycin in short-term treated 
mice Lymphoma sections from Atm-/- mice treated with vehicle or rapamycin for 7 days were 
stained as indicated. [(Reprinted from (146)]
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The second long-term study was similar except we continued dosing the animals daily until the 
animals became moribund and had to be euthanized in accordance with our institutional 
animal care and use committee guidelines, in order to measure whether survival was extended 
due to rescuing lymphomagenesis.  Figure 47 shows our Kaplan-Meier survival curve.  Our 
results demonstrated that rapamycin was efficacious in rescuing lymphomagenesis which had 
an impact on overall survival.  All of the vehicle treated mice were dead by 200 days of age, 
while >50% were still alive beyond 200 days (p<0.001, log-rank test). 
 
4.4 Discussion 
The primary focus of this chapter was evaluating mTORC1 signaling in the aggressive 
lymphomas that arise in Atm-deficient mice.  For the first time, we showed that these 
lymphomas have dysregulated mTORC1 signaling.  It is already well-established that ROS 
plays a key role in the pathogenesis of these tumors, since use of antioxidants such as N-
acetyl cysteine act as chemopreventive agents in these animals via modulating levels of 
oxidative stress (and subsequent DNA damage) (156-159).  In the absence of Atm, this state 
of elevated ROS cannot signal to repress mTORC1 via AMPK, as indicated by the decreased 
level of AMPK phosphorylation seen in the lymphomas.  
 Secondly, our exciting finding that rapamycin rescues ATM-dependent 
lymphomagenesis and extends survival is completely concordant with another large landmark 
study that showed rapamycin could increase longevity of mice of different genetic 
backgrounds by 10-15% in aged mice treated with rapamycin late in life, due to rapamycin 
delaying death from cancer, or diminishing other aging phenotypes (160).   
In our system it is not clear whether the therapeutic effect of rapamycin results from 
rapamycin-induced decrease in ROS levels in thymic cells or rapamycin-induced death of pre-
malignant, activated thymic cells as a consequence of the other activities of rapamycin.  Some 
of these other processes that may be influenced by rapamycin include inhibition of protein 
synthesis, induction of autophagy, inhibition of angiogenesis and modulation of HIF-1α 
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Figure 47: 
 
 
 
Figure 47: Kaplan-Meier survival curve for long-term study of rapamycin as a 
therapeutic for lymphoma [(Reprinted from (146)] 
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expression.  During preparation of our manuscript for publication, a similar study was 
published in a mouse model of a chronic liver disease (hereditary tyrosinemia), which is a 
strong predisposition factor for liver tumorigenesis.  Using the rapalog (rapamycin analog) 
RAD001/everolimus, the authors showed that rapamycin could inhibit the proliferation of 
hepatocytes during chronic liver injury, via engaging the DNA damage response which induces 
cell cycle arrest (161).  Similar to our results, they observed a decrease in p53 expression 
(and p53 transcriptional activity, based on p21 expression), and when the mice were treated 
long-term with RAD001, tumor development was significantly delayed. Taken together these 
results support a model whereby mTOR inhibition can suppress proliferation of cells that have 
accumulated DNA damage, which leads to delayed tumorigenesis in vivo. 
 Our data showing lower levels of apoptosis as measured by TUNEL should perhaps be 
followed up by more detailed studies to determine whether apoptosis is occurring, and the 
dying cellular matter is being removed before it can be detected at the single time-point we 
analyzed.  However, the TUNEL data seems to suggest that a robust apoptotic response is not 
the sole factor in the dramatic anti-tumorigenic response of this short-term administration of 
rapamycin. In addition, autophagy should be examined by electron microscopy and/or LC3 II 
and p62 western blots to determine whether increased autophagy may be functioning as a cell 
death mechanism in this model.  Based on the findings from this study, perhaps the efficacy of 
rapamycin could be increased further via novel combinations of drugs (such as chloroquine), 
especially if autophagy is being utilitzed by the surviving cells as a survival mechanism.   
Regardless of mechanism of delaying tumroigenesis however, this observation may have 
potential therapeutic implications for treatment of AT patients, since mTOR inhibitors are 
currently in a variety of clinical studies and have been approved for certain indications such as 
renal cell carcinoma. 
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Peroxisomal localization of ATM-TSC2 signaling node to regulate pexophagy 
 
5.1 Introduction to problem 
In this part of our work, we aimed to understand where in the cytoplasm ATM signals to TSC2 
in response to ROS, and what the functional consequences of inducing autophagy are.  As 
mentioned in the introductory chapter, ATM has been found at various organelles including the 
peroxisome, centrosome and plasma membrane, whereas TSC2 has not previously been 
definitively localized to a specific endomembrane compartment.   
 The generally accepted model of TSC2 localization involves association with the outer 
surface of an organelle membrane, where this protein can be accessible to AKT and other 
cytoplasmic kinases.  In response to signaling pathways such as induction of PI3K by growth 
factors or mitogens, AKT phosphorylates TSC2 promoting partitioning away from the 
membrane.  This model therefore somewhat limits the possibilities for localization.  Previous 
work from our laboratory has attempted to identify the specific organelle to which TSC2 is 
localized when active, through a combination of in silico approaches and co-
immunofluorescence with well-known markers of different organelles.  In this section I will 
describe the discovery of the peroxisome as a major site for TSC2 GAP towards Rheb, and 
describe ongoing studies that suggest that localization of the ATM:TSC2 signaling node at the 
peroxisome functions as a redox sensor to induce pexophagy if peroxisome number or 
function is perturbed. 
 
5.2 Peroxisome biology 
Peroxisomes, also known as microbodies, were the last of the major organelles to be 
discovered, beginning in the early 1950’s in Rhodin’s doctoral thesis (162) and later 
biochemically characterized by Christian de Duve in 1966 (163, 164).  These discoveries were 
made by careful observation of electron microscopy images, firstly from mouse proximal tubule 
cells, and later in rat liver parenchyma, but later discovered to be present in all cells, where 
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they play a variety of important metabolic roles.  One of the major roles is β-oxidation of fatty 
acids, prostaglandins and leukotrienes which generates significant amount of ROS as a 
byproduct of these reactions.  Other important functions include detoxification of hydrogen 
peroxide and reactive nitrogen species (RNS) via enzymes such as catalase and superoxide 
dismutase, biosynthesis of bile and the phospholipid plasmalogen. A complete listing of all 
these metabolic functions can be found in (165). 
Peroxisomal proteins are targeted to this organelle by means of binding to specific 
import receptor proteins, and imported into the matrix in their finally folded forms.  These 
receptors recognize their cargo based on 3 main types of targeting sequences: PTS1, PTS2 or 
mPTS.  The features of these targeting sequences are summarized in table 3.   
Peroxisome number is tightly regulated in cells both via peroxisomal biogenesis as well 
as degradation via a specific form of autophagy known as pexophagy.  Peroxisomes 
proliferate primately in response to environmental cues including excess lipids, which in 
mammals is triggered via transcriptional regulation by the peroxisomal proliferators activator 
receptor α (PPARα) protein. Approximately 30 genes have been identified that participate in 
either macro- or micro-pexophagy, but most of these are core autophagic machinery (166).  
Signaling pathways that regulate pexophagy have not been well-characterized, particularly in 
mammalian cells, as most of the pexophagy genes have been discovered through studies in 
yeast. 
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Table 3:  
 
Sequence 
Type 
Import 
receptor Consensus sequence 
Location in 
protein 
Peroxisomal 
localization 
information 
PTS1 PEX5 S/A/C - K/R/H - L/M C-terminus Matrix 
PTS2 PEX7 
R/K - L/I/V/Q – XX-L/I/V/H/Q-
L/G/S/A/K-X - Q/H - L/A/F N-terminus Matrix 
mPTS PEX19 
Cluster of basic and possibly 
hydrophobic amino acids 
Near 
transmembrane 
domain Membrane 
 
 
Table 3: Peroxisomal targeting sequence summary 
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Results 
5.31 Predicted peroxisome localization sequences in TSC2, TSC1, mTOR and ATM 
To determine whether the critical pathway members may be localized at the peroxisome, we 
utilized several online in silico tools (which were found through www.peroxisomedb.org) to 
search for any of the peroxisomal targeting sequences as described in previous section (167).  
Table 4 shows the sequences that we found, with bold highlighting the actual sequence that 
matches the consensus.  Note that for TSC1 the sequences we found both have one 
mismatch versus the precise consensus sequence, however we felt that this was sufficient 
rationale to move forward with experimental validation because of what is known about the 
biology of TSC1 and TSC2 functioning as heterodimers within cells. 
 
5.3.2 Experimental evidence for peroxisomal localization of TSC2, TSC1, mTOR and 
ATM 
To begin studying whether TSC2 and other pathway components were localized to the 
peroxisome, we overexpressed Flag-tagged TSC2 and Myc-tagged TSC1 (and reverse for 
TSC1 staining) in HeLa cells and performed standard co-immunofluorescence staining of Flag 
and PMP70, a peroxisomal membrane protein.  As shown in figure 48, we observed a 
punctate cytoplasmic staining, and significant colocalization between wild-type TSC2 and 
PMP70, as well as TSC1 and PMP70.  
In searching through the tuberous sclerosis complex mutation database (found at 
http://chromium.liacs.nl/LOVD2/TSC/home.php?select_db=TSC2)  we found some 28 patients 
with mutations that disrupt the putative PTS1 sequence.  We performed site-directed 
mutagenesis to make 3 of these most common mutations (R1743G, R1743W, R1743Q) and 
when we performed immunofluorescence for these mutants, we found that TSC2 no longer 
stained in the characteristic punctate pattern, nor co-localized with PMP70 (figure 48). 
To confirm these data, we biochemically purified peroxisomes using a differential 
density gradient method, from cultured cells and performed western blots on isolated 
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Table 4:  
 
Protein PTS type Sequence info 
TSC2 PTS1 KWIARLRHIKR 
TSC1 PTS2 KLHSQIRQL or RILELESHL 
ATM PTS1 KNLSRLFPGWK 
mTOR PTS2 RISKQLPQL 
 
 
Table 4: Peroxisome targeting sequences found in proteins of interest 
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peroxisomes, and nuclear, membrane and cytosolic fractions. The nuclear, membrane and 
cytosolic fractionations were performed separately from the peroxisome fractionation to obtain 
the least contamination of organelles in the respective fractions. We overexpressed both wild-
type and mutant TSC2 along with the TSC1, which is necessary for stabilization of TSC2, and 
performed both sets of fractionations as described. The western blots showing significantly 
less membrane-associated and peroxisome-localized mutant TSC2 are shown in figure 49. It 
should be noted that peroxisomes are found in the membrane fraction, since peroxisomes 
pellet alongside the other endomembranes in the ultra-centrifuge spin.  We also used Tsc2-
proficient and Tsc2-deficient MEFs to show that endogenous Tsc2 localizes to the 
peroxisome, and is likewise also found in the membrane fraction.  There is also a portion of 
total TSC2 in the cytoplasm since these cells were cultured in serum-containing media, and 
therefore AKT signaling would have been activated, causing phosphorylated TSC2 to leave 
the membrane fraction. Figure 50 shows endogenous Tsc2 localization within these fractions.  
The other components of the ROS-induced signaling node also localize to the 
peroxisome.  Fractionation of HEK 293 cells, as shown in figure 51, shows that ATM, AMPK, 
mTOR and Rheb can localize to the peroxisome and can be also detected in the membrane 
fraction.
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Figure 48: 
 
 
 
 
Figure 48: Immunofluorescence showing TSC2 and TSC1 colocalization with 
peroxisomal marker PMP70 Hela cells were transfected with (A) Flag-TSC2 and Myc-TSC1 
and co-stained for Flag (red) and PMP70 (green) or (B) Flag-TSC1 and Myc-TSC2 and co-
stained for Flag (red) and PMP70 (green). 
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Figure 49: 
 
 
 
 
Figure 49: Fractionation showing PTS1-disrupted mutants fail to localize correctly to 
membrane and peroxisome fractions.  HEK 203 cells were transfected with Flag-wild-type 
(WT) TSC2 or mutants, and whole cell lysates, membrane fractions, and purified peroxisomes 
were obtained for western analysis as shown. 
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Figure 50: 
 
 
 
 
Figure 50: Fractionation showing endogenous TSC2 localized to the peroxisome and 
membrane fractions Whole cell lysates (lanes 1 and 2), nuclear fractions (N), membrane 
fractions (M), cytosolic fractions (C) and purified peroxisomes (Pex) were isolated from Tsc2-
proficient and Tsc2-deficient MEFs and western analysis was performed.  Catalase is a 
peroxisomal marker, LDH is a cytosolic marker, and Integrin (β1-integrin) is a membrane 
marker.  
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Figure 51: 
 
 
 
 
Figure 51: Fractionation showing ROS-signaling node localized to the peroxisome Whole 
cell lysate (lane 1), nuclear fraction (N), membrane fraction (M), cytosolic fraction (C) and 
purified peroxisomes (Pex) were isolated from HEK 293 cells and western analysis was 
performed.  Catalase is a peroxisomal marker, LDH is a cytosolic marker, and Integrin (β1-
integrin) is a membrane marker.  
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The finding that the PTS1 sequence in TSC2 targets this protein to the peroxisome 
outer membrane, must somehow be resolved with the generally accepted view that PTS1 and 
PTS2 sequences have only been found on peroxisomal matrix proteins such as catalase.  A 
search for potential membrane PTS sequences using the BLOCK algorithm, found only a 
poorly matched stretch of 5 potential amino acid similarities within a 12 amino acid stretch.  
Compared to the PTS1 and PTS2 prediction tools however, it has been more difficult to find 
these potential sites due to the differences in the specificity and sensitivity of the algorithm as 
noted on the website.   
An experimental way of validating whether proteins are localized to the matrix or 
membrane of the peroxisome has been described previously, and is known as the protease 
protection assay. Isolated peroxisomes are Proteinase K treated in the presence or absence of 
Triton X-100 detergent which permeabilizes membranes.  Proteins that are found in the 
membrane would be degraded regardless of the presence of detergent, while matrix proteins 
would be stable unless Triton-X100 was added.  Figure 52 shows the TSC2, TSC1 and ATM 
are all rapidly degraded by Proteinase K treatment, while catalase is not, providing further 
evidence that this signaling node is localized to the outside of the peroxisome membrane, 
allowing TSC2 to be accessible to other cytosolic proteins involved in the many signaling 
pathways that are known to lie upstream of TSC2.. 
 
5.3.3 Loss of peroxisomal targeting sequences perturbs mTORC1 signaling 
Given that we identified patient-derived mutations in TSC2 that would disrupt the PTS1 
sequence, we asked whether this mutant TSC2 was functional in suppressing mTORC1 
signaling.  Using a cellular functional assay similar to the one described in chapter 3, we 
looked at the phosphorylation status of S6K (S6K1) and 4EBP1 in cells transfected with wild-
type and all 3 patient-derived mutations (RG, RQ, RW), and found that while wild-type TSC2 
could potently suppress mTORC1 activity, none of the mutants could suppress mTORC1 (see 
figure 53).
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Figure 52: 
 
 
 
 
Figure 52: Protease protection assay showing that TSC2, TSC1 and ATM are localized 
on the outer surface of the peroxisome Aliquots of purified peroxisomes were isolated from 
HEK 293 cells and subjected to the protease protection assay.  Once the reactions were 
completed, the products were loaded onto gels and western blots were performed as 
indicated.  Catalase is used as a peroxisomal matrix marker and PMP70 is a peroxisomal 
membrane marker. 
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Figure 53: 
 
 
 
 
Figure 53: Functional assay for TSC2 activity towards mTORC1 HEK 293 cells were 
transfected as described in the methods section, and lysates used for western blots as 
indicated.  All three mutants have no GAP activity based on the high levels of mTORC1 
substrate phosphorylation that is equivalent to empty vector + Rheb transfectants. 
107 
To conclusively identify the peroxisome as the organelle where TSC2 is functional, as 
opposed to the alternative hypothesis that the three mutations cause tertiary structure changes 
that alter TSC2’s GAP activity, we reintroduced a PTS1 sequence to the C-terminus of the 
R1743Q construct.  When we performed functional studies on this new construct (RQ-9NT) we 
found that mTORC1 could now be repressed, consistent with the peroxisome being a major 
site of TSC2 activity (figure 54). 
 
5.3.4 Cells from Zellweger syndrome patients possess basal elevated oxidative stress 
and altered mTORC1 regulation 
To determine biological significance of the localization of the ATM-TSC2 signaling node at the 
peroxisome, we looked at cells derived from patients with the Zellweger peroxisome 
biogenesis disorder.  Zellweger’s syndrome is one of the most severe peroxisome biogenesis 
disorders, characterized by a complete absence of peroxisomes, however peroxisome ghost 
structures presumably made of membrane proteins can be observed in some cells (168).  
Since the peroxisome plays vital metabolic roles, most patients experience significant 
problems including neurological abnormalities, hypotonia (poor muscle tone), liver diseases 
and renal cysts, and typically do not survive much beyond 1 year of age (169). 
 We proposed that if mTORC1 suppression at the peroxisome by TSC2 is important for 
maintaining redox homeostasis, that cells lacking peroxisomes such as those from Zellweger 
would possess elevated ROS levels and that similar to Tsc2-deficient cells as shown 
previously, rapamycin could decrease ROS levels.  Figure 55 shows that the Zellweger 
fibroblasts had over 4 fold higher ROS levels, and rapamycin could partially rescue this defect.  
When challenged with a dose-response of H2O2, the Zellweger cells were unable to repress 
mTORC1 until a very high, supra-physiological dose was used (1mM), suggesting that intact 
functional peroxisomes are important for ROS-induced regulation of mTORC1 activity (figure 
56).  However, it is intruiging that ATM can still be activated in the absence of peroxisomes 
quite robustly.
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Figure 54: 
 
 
 
 
 
Figure 54: Reintroducing TSC2 to the peroxisome restores functionality towards 
mTORC1 (A) HEK 293 cells were transfected with Flag-wild-type (WT) TSC2 or mutants and 
Flag-TSC1, and whole cell lysates, membrane fractions, and purified peroxisomes were 
obtained for western analysis as shown. (B) Tsc2-/- MEF cells were transfected as described in 
the methods to perform functional assay for TSC2 activity.  Unlike the RQ mutant which lacks 
GAP activity, the RQ-9NT mutant which relocalizes to the peroxisome regains activity. 
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Figure 55: 
 
 
 
 
Figure 55: Elevated ROS in Zellweger cells, and partial rescue by rapamycin ROS levels 
were measured using DCFDA in control fibroblasts (Ctl, GM15871) and Zellweger syndrome 
(ZW, GM13267) fibroblasts treated with vehicle or 200nM rapamycin for 24 hours.  The 
asterisk represents significance between control and Zellweger cells, and the double asterisks 
represent significance between the vehicle and treated Zellweger cells (both p<0.05, one sided 
t-tests). 
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Figure 56: 
 
 
 
 
 
Figure 56: Dysregulated ROS signaling to mTORC1 in Zellweger cells Control (GM15871) 
and Zellweger syndrome (GM13267) fibroblasts were treated with the indicated doses of H2O2 
for 1 hour prior to harvesting and performing western blots as indicated.  Importantly, the 
Zellweger cells have baseline elevated ATM phosphorylation and this can be induced even 
further, but mTORC1 cannot be suppressed until the highest dose. 
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5.3.5 ROS induction of autophagy induces peroxisome turnover 
Earlier we (and many others) have established that ROS induces autophagy.  With the 
discovery that the ATM:TSC2 signaling node is localized on the periphery of the peroxisome, 
we asked whether peroxisomes could be turned over by pexophagy in response to ROS.  To 
test this hypothesis, we utilized MCF7 GFP-LC3 cells which we treated with H2O2 and followed 
protein levels over a 24 hour time course.  Figure 49 shows that during this time period, we 
saw that consistent with mTORC1 suppression and induction of autophagic flux, that catalase 
expression decreased, suggesting that peroxisomes were being degraded by autophagy.  
Other peroxisomal proteins including TSC2, TSC1, ATM and mTOR were also decreased 
consistent with peroxisome turnover by pexophagy.   
 
5.4 Discussion 
In this chapter we have described a model whereby peroxisomal ATM and TSC2 signal to 
mTORC1 to induce pexophagy.  This work is novel and exciting for a number of reasons. 
Firstly, TSC2 has not previously been localized to a specific endomembrane compartment.  
The recent data on spatial regulation of signaling pathways, such as the amino-acid sensing 
pathway for activating mTOR via recruitment to the lysosomal membrane, where it associates 
with both Rheb and the Rag-Ragulator complex and activate downstream signaling, 
emphasizes the necessity to understand at a sub-cellular level where signaling molecules 
reside and recognize stimulus-dependent mechanisms of action (170). 
 We provided evidence that TSC2 can localize to the peroxisome via a class 1 
peroxisome targeting sequence (PTS1), and that there are mutations in tuberous sclerosis 
complex patients that disrupt this sequence, with important consequences for regulation of 
mTORC1 activity.  When we added an ectopic PTS sequence to the C-terminus of TSC2 
containing one of these patient-derived mutations, we could restore activity, highlighting the 
crucial role played by the peroxisome as a site of TSC2 activity.   
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Figure 57: 
 
 
 
 
 
Figure 57: Degradation of peroxisome proteins in response to ROS (A) MCF7 cells stably 
expressing GFP-LC3 were treated with 0.4mM H2O2 for the indicated times and western blots 
performed as indicated. (B) Graph represents densitometric ratios for the time-dependent 
degradation of several members of the ATM-TSC2 signaling node during autophagy. 
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The discovery of a PTS1 sequence prior to the C-terminus of TSC2 challenges the 
current dogma relating to the location of functional PTS1 sequences, and the precise 
peroxisomal location that peroxin 5 delivers such cargo to.  Our finding that TSC2 contains a 
functional PTS1 sequence, and is delivered to the peroxisomal membrane (based on our 
results from the protease protection experiment) therefore may be surprising.   
While we showed that Rheb can be detected in the peroxisomal fraction, we could not 
find any classical peroxisome targeting sequences.  However, it is already known that Rheb 
contains a CaaX motif which allows farnesylation, which serves as the membrane-targeting 
mechanism, and is necessary for mTORC1 activation (171).  
Peroxisomes are significant ROS-generating organelles due to the activities of 
enzymes involved in β-oxidation, and possess a variety of enzymes responsible for 
scavenging this ROS so that the cell does not become damaged by excessive ROS.  Our data 
support a model whereby peroxisomal ROS signals locally to activate TSC2 via ATM and 
AMPK to repress mTORC1 and induce autophagy which can regulate peroxisome number. In 
the literature, there is not very much known about the mechanisms of peroxisome turnover. 
Most of these studies focus on the role of the PPARα transcription factor which 
transcriptionally activates many genes important in peroxisome biogenesis (172). PPARs are 
activated by drugs such as hypolipidemic fibrates and thiazolidinediones, and in animals, 
withdrawal of these drugs induces autophagy-dependent removal of the excess proliferated 
peroxisomes.  PPAR activation has been shown to result in elevated oxidative stress, due to 
an imbalance in upregulation of ROS-generating enzymes versus ROS-scavenging enzymes, 
which is thought to be a contributing factor to the hepatocarcinogenicity in rodents (173, 174). 
One of the remaining unresolved mechanistic questions is how ATM signals to LKB1 
since we did not find any PTS sequences in LKB1, nor found it localized in peroxisome 
fractions.  One potential explanation for this once activated by ROS, ATM can transiently leave 
the peroxisome membrane to interact with LKB1 in the cytoplasm, and then return to the 
peroxisome to activate AMPK and downstream signaling. It is also possible that LKB1 could 
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activate AMPK in the cytoplasm, and phosphorylated AMPK could traffic back to the 
peroxisome to activate TSC2 to suppress mTOR. Studies are now underway in the laboratory 
to determine which of these possibilities is correct. It would also be interesting to determine 
whether other mechanisms of AMPK activation such as starvation also activate a peroxisomal 
pool of AMPK, or whether this ATM-regulated pathway is specific for ROS. 
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Identification of ATM and TSC2-dependent, but AMPK-independent DNA damage 
signaling pathway to regulate mTOR 
 
6.1 Introduction 
In the first section of this dissertation we described an ATM and TSC2-dependent pathway 
that is engaged in response to ROS to signal to mTORC1. We next asked whether nuclear 
DNA damage, such as that generated by etoposide or ionizing radiation, could also signal via 
this same pathway.  ATM is known to be activated by DNA damage, and as described in the 
opening chapter, can translocate out of the nucleus in response to DNA damage, making this 
a plausible scenario.  In addition, it is already known that DNA damage can activate p53, 
which was reported to be a mechanism of suppressing mTORC1, via AMPK activation, but it 
was not shown whether TSC2 was required for this pathway (134).  In this chapter however, 
we present evidence that in a cell-type dependent manner, DNA damage can induce mTORC1 
suppression without activating AMPK and can do so in p53-deficient cells. 
 There is some literature on the role of LKB1 and AMPK in the DNA damage response, 
which we have published a review on recently, but much of this research did not extend the 
findings downstream of AMPK (175). For example, when the ATM phosphorylation site on 
LKB1 was first discovered, downstream signaling to AMPK and mTORC1 was not analyzed, 
raising the question about whether LKB1 phosphorylation by ATM plays a role in signaling to 
mTORC1 (147).  ATM was also shown to directly phosphorylate AMPK on the LKB1 
phosphorylation site to induce mitochondrial biogenesis (145).  Finally a third potential 
mechanism that has been identified for activating AMPK involves the p53 transcriptional 
targets sestrin 1 and sestrin 2 (144).  More recently, AMPK has been shown to directly 
phosphorylate histone H2B in the nucleus after DNA damage or other stresses, resulting in 
transcription of stress-responsive genes (176). Based on these results, we expected to find 
that in response to DNA damage, ATM could translocate out of the nucleus and into the 
cytoplasm to engage the same pathway as previously identified, or alternatively signal to 
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AMPK in the nucleus, and then phosphorylated AMPK could translocate out to the peroxisome 
where TSC2 is active.  However, our results that indicate AMPK is not necessary for mTORC1 
suppression in a small panel of cell lines tested, indicating that there are other mechanisms 
that exist for DNA damage-induced signaling to mTORC1. 
 
6.2 Results 
6.2.1 Characterization of mTORC1 regulation by DNA damage 
In order to begin studying the mechanisms by which DNA damage regulates mTORC1 we 
began testing several different methods of generating DNA damage in a panel of cell lines to 
characterize the kinetics and magnitude of responses.  Our primary model continued to be 
MCF7 breast carcinoma cells.  Figure 58 shows that etoposide treatment induces mTORC1 
suppression, but only after a 24 hour treatment, while ATM is rapidly activated.  However, 
unlike some of the previous reports, AMPK is not activated, or at least does not remain 
activated until the earliest time point taken (6 hours).  Despite suppression of mTORC1, 
autophagy is not induced by etoposide in MCF7 cells, as seen in figure 59, where no 
significant increase in LC3 II or decrease in p62 is seen. 
 We next looked at the response to ionizing radiation (IR) over a similar time period, and 
we observed a similar profile of signaling, whereby mTORC1 suppression took an extended 
period of time, and did not involve AMPK activation (figure 60).  Due to equipment challenges 
during these studies we also utilized a radiomimetic drug called neocarzinostatin (NCS) which 
is frequently used to activate ATM.  In MCF7 cells, treatment with NCS for 4 hours induced 
ATM activation and mTORC1 suppression, but also did not activate AMPK (figure 61).  In spite 
of mTORC1 suppression, autophagy does not appear to be increased – even though LC3 II 
levels increase slightly, p62 levels increase (figure 62).  Further definitive studies were not 
performed based on this negative preliminary result relating to DNA damage inducing 
autophagy via mTORC1 repression. 
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Figure 58: 
 
 
 
 
Figure 58: mTORC1 signaling in response to etoposide in MCF7 cells MCF7 cells were 
treated with 50µM etoposide for the time periods indicated and western blots performed to 
analyze ATM-AMPK-mTORC1 signaling. 
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Figure 59: 
 
 
 
 
 
Figure 59: Etoposide does not induce autophagy in MCF7 cells MCF7 cells were treated 
with 50µM etoposide for the time periods indicated and western blots performed to analyze 
autophagy induction.  The lysates used in this figure were from the same experiment as figure 
58. 
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Figure 60: 
 
 
 
 
Figure 60: mTORC1 signaling in response to ionizing radiation in MCF7 cells MCF7 cells 
were irradiated with 12 Gy IR and incubated for the time periods indicated and western blots 
performed to analyze ATM-AMPK-mTORC1 signaling. 
 
 
 
120 
Figure 61: 
 
 
 
 
Figure 61: mTORC1 signaling in response to neocarzinostatin in MCF7 cells MCF7 cells 
were treated with 200ng/mL neocarzinostatin or 600ng/mL neocarzinostatin for the time 
periods indicated and western blots performed to analyze ATM-AMPK-mTORC1 signaling. 
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Figure 62: 
 
 
 
 
Figure 62: Neocarzinostatin does not induce autophagy in MCF7 cells MCF7 cells were 
treated with 200ng/mL neocarzinostatin or 600ng/mL neocarzinostatin for the time periods 
indicated and western blots performed to analyze ATM-AMPK-mTORC1 signaling. The lysates 
used in this figure were from the same experiment as figure 61. 
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We characterized signaling pathway regulation in a number of other cell lines to determine 
how generalizable the findings from the MCF7 experiments were.  These results are 
summarized table 5, which shows the significant amount of heterogeneity among cell lines in 
their responsiveness to the various methods we used to generate DNA damage. 
 To begin to dissect out the mechanism, we asked whether TSC2 is required for 
mTORC1 suppression using Tsc2-proficient and Tsc2-deficient MEFs, which as previously 
mentioned are p53-deficient as well, allowing us to rule out p53-dependent pathways.  Figures 
63 and 64 demonstrate that in the absense of Tsc2, there is attenuated mTORC1 suppression 
by etoposide and NCS, suggesting at least 1 Tsc2-dependent pathway exists. 
To confirm the dependence on TSC2 and determine whether ATM plays a role in the 
DNA damage signaling pathway, we used siRNAs targeted against both proteins. Figure 65  
shows that when TSC2 or ATM are depleted, there is a significant decrease in mTORC1 
suppression by IR. Intriguingly when we performed a similar experiment looking at the 
response to etoposide, we saw a striking lack of ATM activation in the TSC2-knockdown cells, 
as seen in figure 66.  Once we had observed this, we attempted to look at whether in Tsc2-/- 
MEFs or kidney tumor cells from the Eker rat (which arise as a result of losing both Tsc2 
alleles) this is also the case; however the phospho-ATM antibody that we used to use for 
mouse and rat cell lines does not work any more, and the replacement antibody only works in 
human samples. 
 
6.2.2 Determination of the mechanism of ATM signaling to mTORC1 in response to 
DNA damage 
Once we had determined that ATM and TSC2 participate in a signaling pathway to regulate 
mTORC1, we focused on determining the mechanism of this signaling. One ATM and TSC2 
independent mechanism we ruled out was mTOR sequestration in the nucleus due to a report 
of a DNA damage inducible gene, promyelocytic leukemia (PML) that is also activated by  
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Table 5:  
Cell Line Drug mTORC1 suppressed? 
AMPK 
activated? 
Autophagy 
induced? 
MCF7 Etoposide Yes - 24 hrs No No 
  IR Yes - 12-24 hrs  No No 
  NCS Yes - 4 hrs No No 
HEK 293 Etoposide No ND ND 
  IR Yes - 1 hr No No 
  NCS Yes - 24 hrs No No 
Tsc2+/+ MEFs Etoposide Yes - 24 hrs No Yes * 
  IR ND ND ND 
  NCS Yes - 2-4 hrs No ND 
Tsc2-/- MEFs Etoposide A little (less than +/+) No Yes * 
  IR ND ND ND 
  NCS No No ND 
• Autophagy induced is not mTORC1-dependent 
• ND = not determined   
 
 
Table 5: Summary of cell-type differences in response to DNA damage 
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Figure 63: 
 
 
 
 
 
Figure 63: mTORC1 response to etoposide in MEFs Tsc2-proficient and Tsc2-deficient 
MEFs were treated with 50µM etoposide 24 hours and western blots performed to analyze 
mTORC1 signaling.  mTORC1 repression is at least partially dependent on Tsc2 expression. 
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hypoxia, and as a result binds and sequesters mTOR in the nucleus away from its targets in 
the cytoplasm (177).  We fractionated MCF7 cells into cytoplasmic and nuclear fractions, after 
treatment with all the damaging agents, we could observe no significant difference in mTOR 
localization between vehicle and drug/IR, suggesting that this PML-mTOR pathway was not 
being engaged, at least in this cell line (figure 67).  We could also rule out the previously 
reported p53-sestrin-AMPK-mTORC1 pathway since AMPK is not activated, and mTORC1 
could be suppressed in p53-deficient MEFs. 
 We next considered the possibility that TSC2 could be a direct ATM phosphorylation 
target, despite the fact that TSC2 was not identified in the unbiased screen for ATM regulated 
proteins recently published (178).  When we performed a scansite search 
(http://scansite.mit.edu) to look for potential novel phosphorylation sites in TSC2, we found 2 
sites that match the ATM consensus sequence (SQ/TQ).  The schematic of human TSC2 
protein shown in figure 68 shows that these putative phosphorylation sites, Ser 403 and Ser 
1379 are in the middle of the protein not within any currently defined functional domain (such 
as the GAP domain). We have constructed a 2A (both serines mutated to alanines) mutant 
and studies are underway to characterize whether TSC2 activity is altered as a consequence 
of losing the ability to be phosphorylated by ATM. 
 
6.3 Discussion 
In this chapter we demonstrate the complexity of damage responses even within a single cell 
line.  In contrast to the previously described pathway for ROS-induced activation of a 
cytoplasmic ATM-LKB1-AMPK-TSC2-mTORC1 pathway, we find that DNA damage induces 
ATM activation leading to TSC2 activation and mTORC1 suppression independent of AMPK 
activation.  This suggests a dual model for damage-induced ATM signaling to mTORC1, as 
illustrated in figure 69.  These results differ from a few isolated reports that claim that AMPK 
mediates a DNA damage induced pathway, but due to the differences in cell lines, damaging  
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Figure 64: 
 
 
 
 
Figure 64: mTORC1 response to neocarzinostatin in MEFs Tsc2-proficient and Tsc2-
deficient MEFs were treated with 200ng/mL neocarzinostatin for 2 or 4 hours and western 
blots performed to analyze mTORC1 signaling.   
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Figure 65: 
 
 
 
 
Figure 65: siRNA validation of role of TSC2 and ATM in mTORC1 suppression by IR  
MCF7 cells were transfected with the indicated siRNAs 48 hours prior to irradiation with 12 Gy. 
After 6 hours of incubation after IR, lysates were made and western blots performed. mTORC1 
repression by IR is dependent on ATM and at least partially dependent on TSC2.
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Figure 66: 
 
 
 
 
Figure 66: siRNA showing a role for TSC2 in ATM activation MCF7 cells were transfected 
with the indicated siRNAs 48 hours prior to addition of etoposide. After 24 hours of incubation, 
lysates were made and western blots performed. 
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Figure 67: 
 
 
 
 
Figure 67: mTOR localization does not change in response to DNA damaging agents 
MCF7 cells treated with the damaging agents (1µM doxorubicin, 50µM etoposide, 7Gy IR) for 
24 hours were fractionated into cytoplasmic (C) and nuclear (N) fractions.  These lysates were 
used for western analysis. 
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agent concentration and time of exposure, our results cannot be directly compared.  Even 
within these reports the role of AMPK in cellular responses is far from clear or even 
necessarily internally consistent – for example, in Sanli et al’s recent paper, where they claimin 
lung, prostate and MCF7 cells that IR activates AMPK independently of LKB1 but in an ATM 
dependent manner, AMPK activation is proposed to be a mechanism of inducing apoptosis 
however compound C treatment (and siRNA knockdown of AMPKα) also sensitizes the cells 
to IR (179).  Zhang et al also identified that the methylating agent, temozolomide, which is 
frequently used in the treatment of gliomas can activate AMPK leading to p53-dependent 
apoptosis (180).  Ultraviolet radiation has also been studied in keratinocytes and there are 
contradictory reports about whether AMPK is activated or inhibited as a result of damage (181, 
182). 
 Our results suggesting that autophagy is not induced directly as a consequence of 
DNA damage signaling to mTORC1 in human cancer cells are also a bit surprising, even 
though there are indeed other potential autophagy regulatory pathways that could be engaged 
by DNA damage that are independent of ATM and TSC2. For example, it is known that p53 
can both positively regulate autophagy (via transcriptional activation of autophagy genes) as 
well as negatively regulate autophagy (via a newly discovered cytoplasmic role in inhibiting 
AMPK activation) (109, 183). It is possible that in MCF7 cells which express wild-type p53, that 
the cytoplasmic function of p53 may be dominant, and therefore in spite of activating ATM and 
p53, p53 may prevent AMPK activation, which maintains autophagy at a low basal level.  
Experiments to tease out this possibility will be a challenge since it is known that genetic 
deletion or potent pharmacological inhibition of p53 also increase autophagy (109), so it may 
be difficult to detect additional stress-induced autophagy without careful optimization/testing of 
different strategies to modulate p53 availability. 
The mechanism of ATM signaling to TSC2 is still unknown.  The predicted ATM 
phosphorylation sites in TSC2 may provide the missing link in this pathway.  If these sites are 
found to be phosphorylated by ATM, our study would have uncovered another cytoplasmic 
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substrate for ATM (figure 68). 
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Figure 68: 
 
 
 
 
 
 
Figure 68: Schematic of TSC2 showing putative ATM phosphorylation sites in relation to 
selected other known features 
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Figure 69: 
 
 
 
 
 
Figure 69: Model for dual mechanisms for signaling from ATM to TSC2 
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Is mTOR suppression and autophagy induction relevant with regard to response to 
therapy in ovarian cancer? 
 
7.1 Introduction 
In the final section of my thesis I will discuss some preliminary studies aimed at understanding 
the clinical relevance of mTORC1 suppression and autophagy induction in cancer therapy.  
While there have been many studies looking at autophagy regulation in some tumor types 
such as breast cancer and prostate cancer, there were relatively few studies in ovarian cancer 
when we began this work.  The main questions we focused on were to identify whether 
cisplatin induced autophagy in ovarian cell lines, and if so is this mTORC1 dependent and 
does autophagy lead to cell death or promote survival. 
 
7.1.1 Ovarian cancer and therapeutics 
Ovarian cancer is a relatively rare but serious cancer type.  According to the American Cancer 
Society, in 2010, there were an estimated 21,880 new cases of ovarian cancer (9th most 
frequent in women) in the US, leading to approximately 14,000 deaths (5th most common in 
women, and most lethal gynecological malignancy) (184).  There are several reasons for the 
disproportionate number of deaths – including the natural history of the disease being 
aggressive, relatively late diagnosis and a lack of effective curative treatment options.  At 
present only about 20% of ovarian cancers are diagnosed while they are still restricted to the 
ovary, when they have an almost 90% chance of being cured by current therapy.  However 
once the disease has spread to the pelvic organs or beyond, the cure rate decreases 
significantly. 
 Currently, virtually all patients diagnosed with ovarian cancer initially undergo surgery 
to remove the bulk of the tumor which also allows accurate staging of the disease, even if 
complete resection is no longer possible.  After recovery from surgery, the most common 
chemotherapeutic protocols that patients receive a combination of a platinum and taxane-
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based treatment, although other agents such as doxorubicin, etoposide and gemcitabine are 
sometimes used.   
 The platinum containing drugs cisplatin and carboplatin (and more recently oxaliplatin) 
have been the mainstay of treatment for more than 30 years for not only ovarian cancer but 
other tumors such as bladder, testicular, HNSCC and NSCLC (185, 186).  These platinum 
containing alkylating agents primarily function as intrastrand crosslinking agents that form 
adduts on the DNA that must be removed in order for replication or transcription to occur.  
Despite cisplatin being approved as a first-line therapy based on impressive results in 
progression-free survival, there are significant toxicities involved with exposure including 
nephrotoxicity and neutropenia, and responses are typically not durable due to acquired 
resistance mechanisms which will be discussed below. Carboplatin is more commonly being 
used nowadays since it has been shown to be equally effective with less side effects than 
cisplatin. 
 Taxanes which are usually used in combination with cisplatin/carboplatin include 
paclitaxel or less commonly docetaxel.  Unlike the DNA damaging agents, these drugs block 
mitosis by disrupting microtubule function.  Paclitaxel binds to β-tubulin which stabilizes the 
GDP-bound form, microtubules are hyper-stabilized due to enhanced polymerization in the 
absence of GTP as well as blocking de-polymerization. The net result is a mitotic arrest and 
induction of apoptosis independently of p53 (187). 
 As mentioned previously, the major clinical problem preventing long-term treatment 
efficacy is the development of resistance to these drugs. Ovarian cancer cells have been 
shown to devise strategies for platinum as well as taxane-resistance, and unsurprisingly since 
these work by different mechanisms, their resistance mechanisms differ. It is interesting that 
often resistance to one class of agent, is correlated with sensitivity to the other (188).  Cisplatin 
resistance is characterized by a number of alterations including: 
• Decreased drug accumulation in cells due to decreased uptake (by both passive and 
active methods such as copper transporters) (189) as well as increased efflux. 
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• Increased glutathione which inactivates cisplatin, by binding and preventing its reaction 
with DNA, also possibly decreasing the level of oxidative stress and increasing DNA 
repair mechanisms (186). 
• Increased DNA repair pathways including nucleotide excision repair, the major 
pathway for platinum adduct removal. 
• Activation of anti-apoptotic pathways (such as Bcl2 overexpression, and activation of 
the PI3K-AKT pathway) and downregulation of pro-apoptotic pathways (such as 
Bax/Bak and p53). 
In contrast, taxane resistance, which is less well characterized at the molecular level, appears 
to be mediated more by alterations in the composition of microtubules.  This can be due to 
changes in the expression of different isoforms of tubulin, mutations in tubulin decreasing 
affinity for taxanes or other post-translational modifications of microtubules.  Expression of 
drug transporter pumps such as P-glycoprotein/other ABC transporters are also thought to 
play a role in taxane-resistance (187). 
 
7.1.2 Role of autophagy in ovarian cancer 
There have been a few reports regarding the role of autophagy induction in ovarian cancer by 
both genetic alternations as well as in response to drugs, and like many other tumor types the 
outcome of autophagy induction is complex and context dependent.  One of the most 
completely characterized responses is the autophagy upregulation due to re-expression of a 
gene called ARHI, which is genetically or epigenetically silenced in approximately 60% of all 
ovarian cancers (190). Dr Bast’s laboratory found that re-expression of ARHI at physiological 
levels, blocked cell growth and induced autophagy by inhibiting PI3K resulting in mTORC1 
suppression, as well as by directly regulating autophagosome formation by upregulating ATG 
4, which is one of the enzymes involved in cleaving LC3 prior to lipidation (191).  Autophagy in 
this scenario led to autophagic cell death in vitro within a few days, however, in vivo, ARHI 
induction led to tumor dormancy and rapid regrowth later once ARHI is downregulated.  This 
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suggests that autophagy can be used as a survival mechanism in vivo, and therefore blocking 
autophagy may be beneficial.  Chloroquine, a drug which inhibits the completion of autophagy 
via increasing the pH in the lysosome was found to delay the regrowth of these dormant cells 
that were depending on autophagy to survive. This finding has potential implications in human 
therapy since chloroquine or its metabolite hydroxychloroquine has been used as an anti-
malarial drug for many years, and despite its low therapeutic index, is thought to be a potential 
radiosensitizing or chemosensitizing agent. 
 In a different cellular context autophagy induction has been linked to improved clinical 
outcome.  During studies on E1A-mediated gene therapy in ovarian cancer, another pathway 
for regulating autophagy was discovered (192). The PEA-15 protein was found to inhibit the 
ERK pathway (due to cytoplasmic sequestration of phosphorylated ERK) which led to 
autophagic cell death.  While these studies did not examine dormancy using a xenograft 
system like in the ARHI studies mentioned previously, the authors did examine PEA-15 
expression in an clinically-annotated tissue microarray and observed that high expression of 
PEA-15 correlated with better overall survival, suggesting that the pro-autophagic nature of 
these tumors was not being utilized as a cancer cell survival mechanism. 
 Targeting cancer cells by increasing their levels of oxidative stress beyond a 
permissible threshold has been proposed as a way of inducing cell death (193, 194).  Ovarian 
cancer cells, even highly chemo-resistant lines such as SKOV3 have been shown to die when 
exposed to ROS-generating drugs such as PEITC or arsenic trioxide (193, 195).  Given the 
numerous links between ROS and autophagy, it seems likely that autophagy in this context 
would participate in cell death, however no studies have been performed directly testing this 
hypothesis. 
 A final study that should be mentioned regarding the role of autophagy in ovarian 
cancer is a recent study published last year regarding the src inhibitor, dasatinib (196).  
Treatment of ovarian cancer cells with dasatinib was shown to induce autophagic cell death in 
a beclin 1 and ATG12 dependent manner involving inhibition of AKT. In xenograft tumors 
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treated with dasatinib, signs of both apoptosis and autophagy were observed by electron 
microscopy, suggesting that in this setting, autophagy can promote death. 
 
7.2 Results 
Firstly we aimed to characterize whether cisplatin and paclitaxel induce repress mTORC1 
repression.  We started these studies off using SKOV3 cells, which we treated with various 
doses of cisplatin for 6 or 24 hours.  Figure 70 shows that similar to the other DNA damaging 
agents discussed in chapter 6, mTORC1 could be suppressed after 24 hours of treatment 
without activating AMPK (using phospho-ACC as a readout of AMPK activity).  One of the 
proposed DNA-damage independent mechanisms of cisplatin cytotoxicity is an early 
generation of ROS (specifically superoxide) (197-199).  ROS has been observed in vitro 
culture of an ovarian cell line (A2780), however the role and magnitude of this response is 
questionable since scavenging the ROS with superoxide dismutase did not increase cell 
survival as would be expected if cellular damage and cell death was occurring due to ROS.  
Based on the lack of activation of AMPK in SKOV3 cells, we next measured whether ROS was 
being generated in response to cisplatin, and found that consistent with no AMPK activation, 
ROS levels were not increased over control (figure 71). In colon cancer, it has been reported 
that cisplatin-induced ROS requires p53 activity (200); these data would suggest that in 
ovarian cancer this is also the case since SKOV3 are p53-deficient. 
 Since autophagy could occur by ROS-dependent or independent mechanisms, we 
looked at whether autophagy was induced upon cisplatin exposure. Figure 72 shows that upon 
treatment with cisplatin, LC3 II levels increased, suggesting increased autophagosome 
formation.  We also looked at p62 levels to measure autophagic flux, and only saw a decrease 
at the highest dose tested, while levels increased slightly in the other samples.  Although p62 
is sometimes a good indicator of autophagic activity, other factors (such as transcriptional  
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Figure 70: 
 
 
 
 
Figure 70: Cisplatin induces mTORC1 suppression without AMPK activation in SKOV3 
cells SKOV3 cells were treated with the indicated doses of cisplatin (CDDP) for 6 or 24 hours 
(with the NT control being harvested with the 6 hour group), or with 0.4mM H2O2 for 1 hour as 
a positive control.  Western analysis shows that at late time points mTORC1 can be 
suppressed but AMPK is not activated. 
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Figure 71: 
 
 
 
 
Figure 71: ROS is not generated by cisplatin in SKOV3 cells SKOV3 cells were treated with 
cisplatin (CDDP) or vehicle for the time periods noted, and ROS levels were measured using 
DCFDA. Bar represents a mean of 5 wells.  The asterisk represents significance between 
cisplatin and vehicle (ANOVA with Tukey’s Multiple Comparisons test), and NS represents a 
non-significant difference versus the control. 
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Figure 72: 
 
 
 
 
Figure 72: Autophagy induction by cisplatin in SKOV3 cells SKOV3 cells were treated with 
the indicated doses of cisplatin (CDDP) for 6 or 24 hours (with the NT control being harvested 
with the 6 hour group), or with 0.4mM H2O2 for 1 hour as a positive control.  Western analysis 
shows that at although LC3 lipidation is increasing there is no impact on autophagic flux. 
These lysates were from the same experiment as in figure 70.. 
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upregulation by Nrf2) may regulate its abundance, making interpretation of this result 
challenging.   
 To deternine whether autophagy induced by cisplatin contributes to cell death or is 
induced as a survival mechanism we took two approaches: firstly we compared an isogenic 
pair of sensitive and resistant cell lines to see if the magnitude of autophagy induction varied 
among them, and secondly, we generated sublines of SKOV3 cells with decreased ATG5 
expression to inhibit the induction of autophagy, and compared the sensitivity of these cells 
with vector transfected controls. 
 The isogenic cell line pair we selected was the Ov2008 and Ov2008/C13 pair 
generated by Dr Steven Howell’s laboratory.  The resistant subline (Ov2008/C13) was 
generated via long term in vitro culture in the presence of cisplatin, which selects for cells that 
can tolerate the damage.  Both cell lines were treated with increasing doses of cisplatin for 24 
hours, and autophagy induction measured by LC3 II and p62 western analysis.  Figure 73 
shows that autophagy was induced in the Ov2008 cell line, which is sensitive to cisplatin, but 
not in the resistant subline. 
 The second approach we took for determining the role of autophagy in cell death 
responses was generation of autophagy-deficient cells.  We used a commercially available 
shRNA construct to knockdown ATG5 expression and isolated multiple clones of these. 
Expression of ATG5 was screened by western blot, as shown in Figure 74, and the clones with 
the best knockdown efficiency were utilized for a cell survival study.  In total 8 ATG5 
knockdown clones were compared to 6 vector-control clones, and cell number was counted 
after 48 hours of exposure to cisplatin, which was left in the media for the duration of the 
experiment.  Figure 75 shows that there was no significant difference in the magnitude of cell 
growth inhibition between vector and ATG5 shRNA clones. 
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Figure 73: 
 
 
 
 
Figure 73: Comparison of autophagy induction in isogenic cisplatin-sensitive and 
cisplatin-resistant cells Ov2008 and Ov2008 C13 cells were treated with the indicated doses 
of cisplatin (CDDP) for 24 hours, and lysates were analyzed by western blots shown above.  
There is a trend for increased autophagic flux in the cisplatin sensitive parental cell line. 
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Figure 74: 
 
 
 
 
Figure 74: ATG5 expression in isolated clones SKOV3 cells stably transfected with ATG5 
shRNA were screened for knockdown of ATG5 by western analysis.  The best clones were 
chosen for cell growth experiment.   
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Figure 75: 
 
 
 
 
Figure 75: Cell death in response to cisplatin does not depend on ATG5 expression in 
SKOV3 cells Cell counts to measure viability after 48 hours of treatment with the indicated 
doses of cisplatin in vector transfected clones (purple) and ATG5 knockdown clones (green).  
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7.3 Discussion 
In this section, we made a number of surprising discoveries regarding the induction of 
autophagy by cisplatin ovarian cancer cells.  For the majority of the experiments we utilized 
the SKOV3 cell line, which is a highly aggressive, multi-drug resistant, p53-deficient serous 
adenocarcinoma-derived cell line with numerous oncogenic drivers including overexpression 
of HER2 and constitutively active AKT (201, 202), which might be predicted to keep basal 
autophagy levels low due to elevated mTOR levels dampening autophagy induction.  We 
showed that LC3 II expression increased moderately from a low baseline level after 24 hours 
of treatment with cisplatin, but p62 levels only decreased at the highest dose of cisplatin 
tested.  
 Cisplatin has been shown to induce cytoprotective autophagy in other cancer cell lines 
including human and rat glioma cells and fibrosarcoma cells via activating AMPK, while in NIH 
3T3 fibroblasts, cisplatin induces a form of autophagic cell death (203, 204).  In contrast to this 
report regarding cancer cells, cisplatin did not activate AMPK in the relatively resistant SKOV3 
cells, indicating significant cell type specificity in response to chemotherapeutic agents.  There 
is some evidence that activating AMPK in ovarian cancer could be a viable therapeutic 
strategy, from several reports that metformin induces cell death in vitro (205, 206) and that the 
chemopreventive drug curcumin can induce apoptosis via activating AMPK and p38 in ovarian 
cancer cells (207).  Based on these promising results further studies are warranted to 
investigate whether these results translate into tumor shrinkage in vivo, and whether 
autophagy plays a role in this mechanism.  Alternatively, it may be possible to target upstream 
signaling to activate AMPK via ROS-induction of ATM for example. 
 The observation that knockdown of ATG5 played no role in cisplatin-induced cell death 
is somewhat surprising.  One potential explanation is that the degree of knockdown even 
though noticeable by western blot was not enough to block autophagy induction in these 
clones. Alternatively, cisplatin could be inducing ATG5-independent forms of autophagy such 
as the ATG5/ATG7-independent forms of macroautophagy identified 2 years ago (208).  This 
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alternative autophagy pathway is ULK1 and beclin 1-dependent and involves Rab9-dependent 
fusion of autophagosomes with vesicles from the golgi and endoplasmic reticulum.  It would be 
worthwhile to make knockdown cells for ULK1, beclin1 and Rab9 before ruling out a role for 
autophagy in the cytotoxicity of cisplatin. 
 The other novel discovery we made was that autophagy was induced more robustly in 
cisplatin-sensitive cells versus an isogenic subline.  Unlike the SKOV3 cells, both the parental 
and resistant subline express wild-type p53, which may or may not participate in the regulation 
of autophagy.  Detailed analysis of the underlying signaling mechanisms remains to be 
completed, but there are some clues in the literature about some of the pathways that might 
be differentially regulated.  These include the JNK and p38 MAPK pathways which can induce 
apoptosis via upregulating FasL if activation of these pathways is prolonged (209).  On the 
other hand, in drug resistant cells, constitutive activation of AKT provides a strong survival 
signal and inhibits apoptosis by blocking the cisplatin-induced mitochondrial accumulation of 
p53 and subsequent early events in apoptosis such as Smac release (210).  IGF-1R, 
mTORC1 and ERK signaling have also been shown to be specifically upregulated in cisplatin 
resistant cells, which would be predicted to again dampen autophagy levels (211, 212).  Taken 
together, these results suggest that perhaps combining inhibitors of growth factor receptors or 
downstream signaling pathways with cisplatin may improve the efficacy of therapy once 
resistance has set in. 
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Summary and future directions 
8.1 Summary 
In this thesis, I unravel a number of novel aspects about damage signaling to the mTORC1 
pathway that may have important implications for cancer therapy and understanding basic cell 
biological mechanisms.  Many cancer chemotherapeutics work by either directly damaging 
DNA or generating oxidative stress, and understanding mechanistically what occurs in 
response to these agents can help us tailor more effective treatment strategies. 
 I started out describing the discovery of an oxidative-stress induced signaling pathway 
that involves activation of a cytoplasmic pool of ATM, which signals to LKB1, AMPK and TSC2 
to repress mTORC1 and induce autophagy. I then went on to show that this signaling node is 
localized at the peroxisome, likely to serve as a ROS homeostasis mechanism to detect when 
peroxisome number or ROS output is too high, and induce pexophagy to remove these 
organelles.  This process may serve to protect the cell from further damage to proteins and 
organelles.  Next I uncovered another non-overlapping pathway that is activated in response 
to DNA damage that is ATM and TSC2-dependent but does not involve activating AMPK.  The 
precise mechanism for this is unclear though a potential ATM:TSC2 interaction was proposed 
based on in silico analysis and identification of putative phosphorylation sites.    Finally I 
investigated whether in ovarian cancer cells cisplatin affected mTORC1 and autophagy based 
on knowing that ATM would be activated either by the DNA damage or potentially by oxidative 
stress.  I showed that in the SKOV3 model at least, that cisplatin does not induce ROS, nor the 
ROS-signaling pathway, but that mTORC1 could be repressed with slow kinetics similar to the 
DNA damaging agents in MCF7 cells.  However the functional consequence of mTORC1 
suppression by cisplatin is still unclear based on our results with the ATG5-knockdown clones 
showing no difference in cell death after cisplatin exposure when compared with the vector-
transfected clones. 
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8.2 Future Directions 
The future areas of research I forsee fall into a few separate areas: 
• Mechanism of ROS-induced ATM activation 
• The role and regulation of pexophagy 
• Determining the DNA damage-regulated pathway(s) 
• Revisiting targeting ATM in cancer integrating the newly discovered ATM-autophagy 
knowledge.  
Each of these areas will now be described more thoroughly. 
 
8.2.1 Mechanism of ROS-induced ATM activation 
One of the critical questions still remaining in the field is how ATM is differentially regulated by 
ROS versus DNA damage. As mentioned in the first chapter, the classical model for ATM 
activation posits that an inactive dimer is activated upon DNA double-strand breaks to become 
active monomers.  In contrast, Tanya’s Paull’s group identified a cysteine in ATM that is 
directly oxidized by ROS, and as a result ATM molecules form disulfide bonds, to create an 
active dimer.  Based on our fractionation data that ATM can be phosphorylated in the 
cytoplasm and nucleus rapidly in response to ROS, the obvious question is whether these 2 
species are equivalent, or whether the cytoplasmic pool is really the disulfide-linked active 
dimer, and the nuclear pool is a monomer or some combination of both forms.  To answer this 
question, some of the mutant ATM constructs and reconstitution cell lines that Tanya Paull’s 
laboratory generated could be useful tools for more detailed cellular localization analysis when 
combined with the ability to detect monomers versus dimers using native gel conditions that 
they have optimized.  Secondly to build on this topic, it would be interesting to know whether 
peroxisomal ATM that is activated by ROS is a monomer or dimer, how it is modified and the 
mechanisms of how it travels to the peroxisome (ie whether the putative PTS1 sequence 
identified previously in ATM actually mediates binding to PEX5, or whether another membrane 
PTS sequence exists that allows binding to PEX19). 
150 
 At a conference I recently attended, some interesting research was presented 
regarding a small pool of mitochondrial localized ATM, which may explain some of the 
mitochondrial dysfunction phenotypes seen in ATM-deficient cells.  Given that we have linked 
ATM to autophagy, it would be interesting to know whether ATM participates in the regulation 
of mitophagy in response to ROS in an analogous manner to our model for regulation of 
pexophagy. 
 Finally, our results in the fibroblasts from Zellweger syndrome patients present an 
interesting question regarding a peroxisome-independent mechanism of ATM activation by 
ROS.  The cellular localization of phosphorylated ATM needs to be analyzed in these cells to 
begin to understand this mechanism. The baseline moderate level of phosphorylated ATM in 
these cells relative to the control cells suggest that the intracellular milieu is tipped towards a 
damaged state even in the absence of exogenous damaging agents, which might be 
correlated with some of the disease phenotypes, and therefore perhaps treatment with 
rapamycin or other agents to decrease ROS might be a logical therapeutic option. 
 
8.2.2 The role and regulation of pexophagy 
The study of pexophagy in mammalian systems is still at a very elemental level, and there are 
few if any links to disease.  Given the wide spectrium of diseases associated with aberrant 
redox homeostasis and autophagy, it would be surprising if pexophagy dysregulation failed to 
lead to disease.  Peroxisome number has not been analyzed in cancer, perhaps due to a 
paucity of accurate methods to do so in archival samples and likely the overall lack of 
awareness of the importance of this organelle in basic metabolism. Cancer cells are known to 
possess aberrantly wired metabolic networks, so a whole area of research into peroxisome 
biology with regard to metabolic networks may be a future direction to explore.  
 A more immediate area of investigation will need to focus on providing in vivo evidence 
of ROS-induced pexophagy, whether that is via the ATM-LKB1-AMPK-TSC2-mTORC1 
pathway or otherwise. 
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8.2.3 Determination of p53-independent DNA-damage-induced mTORC1 suppression 
mechanisms 
In the DNA damage chapter of this thesis I presented evidence for multiple mechanisms of 
mTORC1 suppression by DNA damage, beyond the previously identified p53-dependent 
pathways.  These mechanisms need to be explored further. To follow up on the putative direct 
ATM phosphorylation sites that have been proposed, we have generated a TSC2 mutant 
construct that lacks these sites. Some type of functional assay will need to be performed to 
compare the DNA damage-regulated activity of this mutant with the wild-type, and if these 
studies provide preliminary evidence of some role, then more detailed studies will need to be 
performed to determine whether ATM and TSC2 interact in cells (e.g. by immunoprecipitation).  
In addition, the pan-ATM substrate antibody might be used on Tsc2+/+ and Tsc2-/- cells to 
determine whether TSC2 is a potential substrate, which could be validated by generating a 
phospho-specific antibody to these sites and showing that the signal increases in response to 
DNA damage. 
 
8.2.4 ATM as a therapeutic target in cancer 
ATM has been proposed as a target for chemo- or radiosensitization in cancer, based on the 
observation that AT-cells are hypersensitive to radiation.  Further rationale for targeting ATM 
has been proposed based on the cytoplasmic functions of ATM in regulating AKT signaling, 
since although AKT would be an ideal target in a large variety in cancer cells, direct AKT 
inhibitors have been too non-specific.  Last year it was shown that an ATM chemical inhibitor 
could also inhibit AKT signaling, resulting in tumor growth inhibition via inducing cell cycle 
arrest and mTORC1 inhibition, making this a more worthwhile potential approach to try out in 
preclinical and clinical models (213).  Since ATM not only regulates apoptosis but autophagy, 
future studies with ATM inhibitors should focus on identifying the role of both processes in the 
cellular responses/lack of response, so that if autophagy induction limits the efficacy 
combinations with autophagy inhibitors can be tested.
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